[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 200
1. Polton GA, Brearley MJ: Clinical stage, therapy, and prognosis in canine anal sac gland carcinoma. J Vet Intern Med; 2007 Mar-Apr;21(2):274-80

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical stage, therapy, and prognosis in canine anal sac gland carcinoma.
  • BACKGROUND: Reports of canine anal sac gland carcinoma (ASGC) describe varied clinical presentations and management and differing responses to therapy.
  • A unifying approach to clinical stage determination and management of this disease has yet to be presented.
  • METHODS: A simplified clinical stage system and a management algorithm for canine ASGC were derived from retrospective evaluation of a cohort of 80 dogs; applicability of both was then prospectively evaluated in a cohort of 50 dogs.
  • In both retrospective and prospective analyses, the modified clinical stage scheme revealed a significant association with survival time.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17427388.001).
  • [ISSN] 0891-6640
  • [Journal-full-title] Journal of veterinary internal medicine
  • [ISO-abbreviation] J. Vet. Intern. Med.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


2. Krengli M, Milia ME, Turri L, Mones E, Bassi MC, Cannillo B, Deantonio L, Sacchetti G, Brambilla M, Inglese E: FDG-PET/CT imaging for staging and target volume delineation in conformal radiotherapy of anal carcinoma. Radiat Oncol; 2010;5:10
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG-PET/CT imaging for staging and target volume delineation in conformal radiotherapy of anal carcinoma.
  • BACKGROUND: FDG-PET/CT imaging has an emerging role in staging and treatment planning of various tumor locations and a number of literature studies show that also the carcinoma of the anal canal may benefit from this diagnostic approach.
  • We analyzed the potential impact of FDG-PET/CT in stage definition and target volume delineation of patients affected by carcinoma of the anal canal and candidates for curative radiotherapy.
  • METHODS: Twenty seven patients with biopsy proven anal carcinoma were enrolled.
  • Pathology was squamous cell carcinoma in 20 cases, cloacogenic carcinoma in 3, adenocarcinoma in 2, and basal cell carcinoma in 2.
  • RESULTS: PET/CT fused images led to change the stage in 5/27 cases (18.5%): 3 cases from N0 to N2 and 2 from M0 to M1 leading to change the treatment intent from curative to palliative in a case.Based on PET/CT imaging, GTV and CTV contours changed in 15/27 (55.6%) and in 10/27 cases (37.0%) respectively.
  • CONCLUSIONS: FDG-PET/CT has a potential relevant impact in staging and target volume delineation of the carcinoma of the anal canal.
  • Clinical stage variation occurred in 18.5% of cases with change of treatment intent in 3.7%.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma / pathology. Neoplasm Staging / methods. Radiotherapy Planning, Computer-Assisted / methods. Radiotherapy, Conformal

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiother Oncol. 2001 Oct;61(1):15-22 [11578724.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):824-30 [19117696.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):893-900 [15936575.001]
  • [Cites] Mol Imaging Biol. 2005 Jul-Aug;7(4):309-13 [16028002.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):720-5 [16626889.001]
  • [Cites] Technol Cancer Res Treat. 2007 Feb;6(1):31-6 [17241098.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Sep 1;69(1):155-62 [17707268.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Apr 1;70(5):1423-6 [17931795.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):180-6 [17996387.001]
  • [Cites] Med Phys. 2008 Apr;35(4):1207-13 [18491512.001]
  • [Cites] Radiother Oncol. 2008 Jun;87(3):376-82 [18453023.001]
  • [Cites] Br J Cancer. 2009 Mar 10;100(5):693-700 [19259091.001]
  • [Cites] Strahlenther Onkol. 2009 Apr;185(4):254-9 [19370429.001]
  • [Cites] Br J Radiol. 2009 Jun;82(978):509-13 [19153180.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):281-8 [15241824.001]
  • (PMID = 20137093.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Other-IDs] NLM/ PMC2851594
  •  go-up   go-down


3. Mistrangelo M, Bellò M, Mobiglia A, Beltramo G, Cassoni P, Milanesi E, Cornaglia S, Pelosi E, Giunta F, Sandrucci S, Mussa A: Feasibility of the sentinel node biopsy in anal cancer. Q J Nucl Med Mol Imaging; 2009 Feb;53(1):3-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Feasibility of the sentinel node biopsy in anal cancer.
  • AIM: Anal cancer is a rare neoplasm.
  • According to a European Organization for Research and Treatment of Cancer multivariate analysis, synchronous inguinal lymph node metastasis occurs in 10-25% of patients and constitutes an independent prognostic factor for local failure and overall mortality.
  • METHODS: Inguinal lymph node status was assessed using the sentinel node technique in 35 patients with anal cancer.
  • RESULTS: Histology revealed 23 squamous carcinomas, 10 basaloid carcinomas, 1 squamous carcinoma with basaloid areas and 1 spinocellular epithelioma associated with areas of Bowen's disease.
  • Disease stage was T1 in 5 patients, T2 in 18, T3 in 11 and T4 in 1 patient.
  • CONCLUSIONS: Given the correlation between prognosis and node involvement, sentinel node biopsy can be considered a simple method for adequate pretreatment staging of anal carcinoma.
  • [MeSH-major] Anus Neoplasms / diagnosis. Sentinel Lymph Node Biopsy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Feasibility Studies. Female. Follow-Up Studies. Humans. Inguinal Canal / pathology. Lymphatic Metastasis / diagnosis. Male. Middle Aged. Neoplasm Staging. Recurrence

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18337684.001).
  • [ISSN] 1824-4785
  • [Journal-full-title] The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutical Chemistry and Biology
  • [ISO-abbreviation] Q J Nucl Med Mol Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


Advertisement
4. Joseph DA, Miller JW, Wu X, Chen VW, Morris CR, Goodman MT, Villalon-Gomez JM, Williams MA, Cress RD: Understanding the burden of human papillomavirus-associated anal cancers in the US. Cancer; 2008 Nov 15;113(10 Suppl):2892-900
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Understanding the burden of human papillomavirus-associated anal cancers in the US.
  • BACKGROUND: Anal cancer is an uncommon malignancy in the US; up to 93% of anal cancers are associated with human papillomavirus.
  • METHODS: Cases diagnosed between 1998 and 2003 from 39 population-based cancer registries were analyzed.
  • The following anal cancer histologies were included in the analysis: squamous cell, adenocarcinoma, and small cell/neuroendocrine carcinomas.
  • RESULTS: From 1998 through 2003, the annual age-adjusted invasive anal cancer incidence rate was 1.5 per 100,000 persons.
  • Squamous cell carcinoma (SCC) was the most common histology overall, accounting for 18,105 of 21,395 (84.6%) cases of anal cancer.
  • Incidence rates of anal SCC increased 2.6% per year on average.
  • The majority of SCC cases were diagnosed at the in situ or localized stage (58.1%).
  • API were more likely to be diagnosed with regional or distant stage disease than were other racial/ethnic groups (27.5% and 11.8%, respectively).
  • CONCLUSIONS: Rates of anal SCC varied by sex, race, and ethnicity.
  • A higher proportion of API were diagnosed at regional/distant stage.
  • Continued surveillance and additional research are needed to assess the potential impact of the HPV vaccine on the anal cancer burden in the US.

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] Cancer. 2000 Mar 15;88(6):1464-9 [10717631.001]
  • [Cites] Clin Infect Dis. 2002 Nov 1;35(9):1127-34 [12384848.001]
  • [Cites] AIDS. 2003 Feb 14;17(3):311-20 [12556684.001]
  • [Cites] Prev Med. 2003 May;36(5):555-60 [12689800.001]
  • [Cites] Dis Colon Rectum. 2003 Nov;46(11):1517-23; discussion 1523-4; author reply 1524 [14605572.001]
  • [Cites] Cancer Causes Control. 2003 Nov;14(9):837-46 [14682441.001]
  • [Cites] Lancet Oncol. 2004 Mar;5(3):149-57 [15003197.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):270-80 [15241823.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):281-8 [15241824.001]
  • [Cites] N Engl J Med. 1987 Oct 15;317(16):973-7 [2821396.001]
  • [Cites] Gastroenterology. 1988 Jul;95(1):107-11 [2836255.001]
  • [Cites] Am J Epidemiol. 1992 Jan 15;135(2):180-9 [1311142.001]
  • [Cites] Am J Epidemiol. 1992 Jul 1;136(1):54-8 [1329500.001]
  • [Cites] Am J Epidemiol. 1994 Apr 15;139(8):772-80 [8178790.001]
  • [Cites] Am J Epidemiol. 1994 Jul 1;140(1):12-9 [8017399.001]
  • [Cites] N Engl J Med. 1997 Nov 6;337(19):1350-8 [9358129.001]
  • [Cites] Semin Cancer Biol. 1998 Aug;8(4):307-13 [9870037.001]
  • [Cites] Cancer Res. 1999 Feb 1;59(3):753-7 [9973228.001]
  • [Cites] JAMA. 1999 May 19;281(19):1822-9 [10340370.001]
  • [Cites] Clin Infect Dis. 2006 Jul 15;43(2):223-33 [16779751.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2006 Oct 27;55(42):1145-8 [17065979.001]
  • [Cites] Stat Methods Med Res. 2006 Dec;15(6):547-69 [17260923.001]
  • [Cites] Lancet Oncol. 2007 Apr;8(4):311-6 [17395104.001]
  • [Cites] Am J Surg Pathol. 2007 Jun;31(6):919-25 [17527081.001]
  • [Cites] Clin Microbiol Rev. 2007 Jul;20(3):478-88, table of contents [17630336.001]
  • [Cites] Sex Transm Infect. 2007 Jul;83(4):257-66 [17664359.001]
  • [Cites] Cancer Causes Control. 2007 Dec;18(10):1175-86 [17805982.001]
  • [Cites] Cancer. 2008 Nov 15;113(10 Suppl):2841-54 [18980203.001]
  • [Cites] Dermatol Ther. 2005 Jan-Feb;18(1):67-76 [15842614.001]
  • [Cites] Dan Med Bull. 2002 Aug;49(3):194-209 [12238281.001]
  • (PMID = 18980293.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] None / None / / N01 PC035137; United States / NCCDPHP CDC HHS / DP / U50 DP424071; United States / NCI NIH HHS / PC / N01 PC035137; United States / NCCDPHP CDC HHS / DP / U50 DP424071-04
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS104103; NLM/ PMC2729501
  •  go-up   go-down


5. Deniaud-Alexandre E, Touboul E, Tiret E, Sezeur A, Hannoun L, Houry S, Huguet F, Pène F, Parc R, Schlienger M: [Epidermoid carcinomas of anal canal treated with radiation therapy and concomitant chemotherapy (5-fluorouracil and cisplatin)]. Cancer Radiother; 2006 Dec;10(8):572-82
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epidermoid carcinomas of anal canal treated with radiation therapy and concomitant chemotherapy (5-fluorouracil and cisplatin)].
  • [Transliterated title] Carcinomes épidermoïdes du canal anal traités par association concomitante de radiothérapie et de chimiothérapie. Evaluation des résultats fonctionnels.
  • PURPOSE: To evaluate our results after radiation therapy and concomitant chemotherapy in terms of local control, survival and toxicity in patients with anal cancer.
  • The T-stage according to the 2001 UICC classification were: 2 T1, 26 T2, 25 T3, and 7 T4.
  • LC rate with a good anal function scoring (score 0 and 1) was 70%.
  • Among 43 pts who preserved their anus, 98% had a good anal function scoring.
  • Late severe complication was observed in 3 pts: 2 pts with painful necrosis of the anus requiring colostomy and 1 pt with grade 3 rectal bleeding.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / pathology. Antimetabolites, Antineoplastic / administration & dosage. Brachytherapy. Cisplatin / administration & dosage. Combined Modality Therapy. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Follow-Up Studies. HIV Seropositivity. Humans. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17110148.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


6. Oehler-Jänne C, Seifert B, Lütolf UM, Ciernik IF: Local tumor control and toxicity in HIV-associated anal carcinoma treated with radiotherapy in the era of antiretroviral therapy. Radiat Oncol; 2006;1:29
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local tumor control and toxicity in HIV-associated anal carcinoma treated with radiotherapy in the era of antiretroviral therapy.
  • PURPOSE: To investigate the outcome of HIV-seropositive patients under highly active antiretroviral treatment (HAART) with anal cancer treated with radiotherapy (RT) alone or in combination with standard chemotherapy (CT).
  • 10 TNM-stage and age matched HIV-seronegative patients (1992-2003) were compared with the 10 HIV-seropositive patients.
  • Pattern of care, local disease control (LC), overall survival (OS), cancer-specific survival (CSS), and toxicity were assessed.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Anus Neoplasms / virology. HIV Infections / complications. HIV Infections / drug therapy. Radiotherapy / methods


7. Tournier-Rangeard L, Peiffert D, Lafond C, Mege A, Metayer Y, Marchesi V, Buchheit I, Uwer L, Conroy T, Kaminsky MC: [Long-term results and prognostic factors of squamous cell carcinoma of the anal canal treated by irradiation]. Cancer Radiother; 2007 Jun;11(4):169-77
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term results and prognostic factors of squamous cell carcinoma of the anal canal treated by irradiation].
  • [Transliterated title] Résultats à long terme et facteurs pronostiques des carcinomes épidermoïdes du canal anal traités par irradiation.
  • PURPOSE: To analyze the prognostic factors of loco regional control (LRC), specific survival (SS) and sphincter conservation (SC) of patients treated by curative and conservative irradiation for an epidermoid cancer of anal canal in our institution.
  • Forty-three pts were stage I, 154 stage II, 31 stage IIIA and 53 stage IIIB.
  • Five-years-LRC were 71.5% (88% for stage I, 69% for stage II, 77%, for stage IIIA and 60% for stage IIIB).
  • [MeSH-major] Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / radiotherapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17400501.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


8. Abramowitz L, Mathieu N, Roudot-Thoraval F, Lemarchand N, Bauer P, Hennequin C, Mitry E, Romelaer C, Aparicio T, Sobhani I: Epidermoid anal cancer prognosis comparison among HIV+ and HIV- patients. Aliment Pharmacol Ther; 2009 Aug 15;30(4):414-21
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermoid anal cancer prognosis comparison among HIV+ and HIV- patients.
  • BACKGROUND: Previous studies suggest a poor prognosis of epidermoid anal cancer in HIV+ patients.
  • AIM: To investigate the long-term outcome of epidermoid anal cancer in HIV+ and HIV- patients in the highly active antiretroviral treatment (HAART) era.
  • METHODS: We included all patients with epidermoid anal cancer referred to six hospitals from 1998 to 2004.
  • No significant differences were observed in the tumour stage, pelvic radiotherapy dose or concomitant chemotherapy, according to the HIV status.
  • CONCLUSIONS: The clinical outcome of HIV+ patients with epidermoid anal cancer is similar to that of HIV- patients.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy. HIV Infections / drug therapy. HIV Seropositivity / complications


9. Hatfield P, Cooper R, Sebag-Montefiore D: Involved-field, low-dose chemoradiotherapy for early-stage anal carcinoma. Int J Radiat Oncol Biol Phys; 2008 Feb 1;70(2):419-24
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Involved-field, low-dose chemoradiotherapy for early-stage anal carcinoma.
  • PURPOSE: To report the results of patients with early-stage anal cancer treated using a low-dose, reduced-volume, involved-field chemoradiotherapy protocol.
  • All were considered to have Stage N0 disease radiologically.
  • CONCLUSION: The results of our study have shown that for patients with anal carcinoma who have residual microscopic or very-small-volume disease, a policy of low-dose, reduced-volume, involved-field chemoradiotherapy produces excellent local control and disease-free survival, with low rates of acute and late toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17919842.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


10. Lund JA, Wibe A, Sundstrom SH, Haaverstad R, Kaasa S, Myrvold HE: Anal carcinoma in mid-Norway 1970-2000. Acta Oncol; 2007;46(7):1019-26
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal carcinoma in mid-Norway 1970-2000.
  • The treatment of anal carcinoma changed from surgery to chemoradiotherapy 20-25 years ago.
  • The aim of this observational study was to compare surgery with chemoradiotherapy with regard to side effects, local recurrence and survival during and after the implementation of a new treatment policy for anal carcinoma.
  • The study includes all 111 patients with anal carcinoma diagnosed between 1970 and 2000 in mid-Norway.
  • Stage, age and treatment were all significant indicators of survival in uni- and multivariable analysis.
  • Late side effects were moderate after combined therapy; only one patient preferred getting a stoma due to radiation damage of the anal sphincter.
  • The change of strategy for anal cancer treatment from surgery to combined therapy has probably reduced local recurrence and improved survival.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma / therapy. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17882558.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  •  go-up   go-down


11. Ficari F, Fazi M, Garcea A, Nesi G, Tonelli F: Anal carcinoma occurring in Crohn's disease patients with chronic anal fistula. Suppl Tumori; 2005 May-Jun;4(3):S31
MedlinePlus Health Information. consumer health - Crohn's Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal carcinoma occurring in Crohn's disease patients with chronic anal fistula.
  • This paper reports six patients with perianal Crohn's disease (CD), who developed anal cancer in chronic anal fistulas.
  • Tumors have been often diagnosed at an advanced stage and had a worse prognosis than cancers arising in the general population as tumor symptoms may mimic symptoms of CD, resulting in delay in diagnosis.
  • Patients with perianal CD should undergo a careful surveillance program for ano-rectal carcinoma, including routine biopsy of any suspected lesion.
  • [MeSH-major] Anus Neoplasms / etiology. Crohn Disease / complications. Rectal Fistula / complications

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437885.001).
  • [ISSN] 2283-5423
  • [Journal-full-title] I supplementi di Tumori : official journal of Società italiana di cancerologia ... [et al.]
  • [ISO-abbreviation] Suppl Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


12. Martin FT, Kavanagh D, Waldron R: Squamous cell carcinoma of the anal canal. Surgeon; 2009 Aug;7(4):232-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma of the anal canal.
  • Squamous cell carcinoma ofthe anal canal represents 1.5% of all malignancies affectingthe gastrointestinal tract.
  • CLINICAL MANAGEMENT: Historically abdominoperineal resection had been the treatment of choice with local resection reserved for early stage disease.
  • Work by Nigro et al. has revolutionised how we currently manage carcinoma of the anal canal, demonstrating combined modality chemoradiotherapy as an appropriate alternative to surgical resection with the benefit of preserving sphincter function.
  • [MeSH-major] Anus Neoplasms / diagnosis. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19736891.001).
  • [ISSN] 1479-666X
  • [Journal-full-title] The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland
  • [ISO-abbreviation] Surgeon
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Scotland
  • [Number-of-references] 57
  •  go-up   go-down


13. Barriger RB, Calley C, Cárdenes HR: Treatment of anal carcinoma in immune-compromised patients. Clin Transl Oncol; 2009 Sep;11(9):609-14
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of anal carcinoma in immune-compromised patients.
  • This study was undertaken to evaluate local control (LC), overall survival (OS) and toxicity in immune-compromised patients with anal carcinoma treated with radiotherapy with or without chemotherapy.
  • METHODS: We identified 25 patients with anal carcinoma and human immunodeficiency virus (HIV) infection or history of solid-organ transplant on chronic medical immune-suppression.
  • AJCC T-stages were Tis (4%), T1 (8%), T2 (58%) and T3 (29%).
  • T-stage and CD4 level in HIV-positive patients predict for LC.
  • T-stage and TT predict for OS.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma / therapy. Immunocompromised Host

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • HIV InSite. treatment guidelines - Palliative Care of Patients with HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19776001.001).
  • [ISSN] 1699-3055
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


14. Khanfir K, Ozsahin M, Bieri S, Cavuto C, Mirimanoff RO, Zouhair A: Patterns of failure and outcome in patients with carcinoma of the anal margin. Ann Surg Oncol; 2008 Apr;15(4):1092-8
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of failure and outcome in patients with carcinoma of the anal margin.
  • BACKGROUND: To evaluate the outcome of patients with carcinoma of anal margin in terms of recurrence, survival, and radiation toxicity.
  • METHODS: A series of 45 consecutive patients, with anal margin carcinoma treated between 1983 and 2006 with curative intent at two institutions, was retrospectively analyzed.
  • The overall anal conservation rate was 80% for the whole series.
  • There was no significant association between local recurrence and patient age, histological grade, tumor size, T stage, overall treatment time, RT dose, or chemotherapy.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Basal Cell / therapy. Carcinoma, Squamous Cell / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / surgery. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Treatment Failure. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18231838.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Takashima A, Shimada Y, Hamaguchi T, Ito Y, Masaki T, Yamaguchi S, Kondo Y, Saito N, Kato T, Ohue M, Higashino M, Moriya Y, Colorectal Cancer Study Group of the Japan Clinical Oncology Group: Current therapeutic strategies for anal squamous cell carcinoma in Japan. Int J Clin Oncol; 2009 Oct;14(5):416-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current therapeutic strategies for anal squamous cell carcinoma in Japan.
  • BACKGROUND: In Western countries, chemoradiotherapy (CRT) is well established as the standard therapy for stages II/III anal squamous cell carcinoma (ASCC).
  • The Colorectal Cancer Study Group of the Japan Clinical Oncology Group (JCOG-CCSG) conducted a survey to determine the current therapeutic strategies for ASCC in Japan.
  • Detailed information was obtained for 55 subjects; 25 (45%) had stage II ASCC and 30 (55%) had stage III ASCC.
  • [MeSH-major] Anus Neoplasms / therapy. Asian Continental Ancestry Group. Carcinoma, Squamous Cell / therapy. Digestive System Surgical Procedures

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19856049.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Japan
  • [Investigator] Kondo Y; Ohtsuka K; Shiiba K; Sato T; Yoshimi F; Kotake K; Sawada T; Mochizuki H; Konishi F; Saito N; Moriya Y; Masaki T; Aoki T; Takahashi K; Hasegawa H; Kenichi S; Sumiyama Y; Sato T; Akaike M; Kudo S; Yamada T; Munakata Y; Shigeski Y; Kato T; Maeda K; Koizumi K; Monden M; Ohue M; Higashino M; Tanigawa M; Fukunaga M; Kato T; Okamura S; Kimura H; Okajima M; Takakura N; Tanada M; Shirouzu K; Kitano S
  •  go-up   go-down


16. Djellali L, Larbaoui B, Boukerche A, Ghazi S, Chaiba I, Meziane N, Yekrou D, Youcef DF: Preoperative concomitant chemoradiotherapy with oxaliplatin and 5-fluorouracil in locally advanced rectal carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e15108

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative concomitant chemoradiotherapy with oxaliplatin and 5-fluorouracil in locally advanced rectal carcinoma.
  • : e15108 Background: Preoperative concomitant chemoradiotherapy has shown to improve local control and sphincter preservation with decreased acute toxicity compared with postoperative treatment in locally advanced rectal carcinoma.
  • Secondary endpoint was sphincter preservation and toxicity Methods: Inclusion criteria: rectal adenocarcinoma <12 cms from anal verge, clinical stage T3-4, adequate renal, hematological and liver function.
  • Clinical stage (determined by CT or RMI): T3: 66.6% and T4: 33.3%.
  • Tumor location (from anal verge): < 6 cm in 10pts, >6 cm in 5pts.
  • Main adverse effects (NCI-CTC): diarrhea G3-4: 14.2%, sensitive peripheral neurotoxicity G1: 26.6%, nausea/vomiting G3-4: 11%, Anemia G3-4: 7.1%, neutropenia G3-4: 14.2% Conclusions: Preliminary results show that preoperative concomitant chemoradiotherapy with oxaliplatin and 5FU-folinic acid is an effective regimen with an acceptable safety profile for locally advanced rectal cancer, leading to a high probability of tumor downstaging.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964340.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Hammad N, Philip PA, Shields AF, Heilbrun LK, Venkatramanamoorthy R, El-Rayes BF: A retrospective review of squamous cell carcinoma of the anal canal in HIV-positive and HIV-negative patients. J Clin Oncol; 2009 May 20;27(15_suppl):e15586

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A retrospective review of squamous cell carcinoma of the anal canal in HIV-positive and HIV-negative patients.
  • : e15586 Background: Human immunodeficiency virus (HIV) infected patients (pts) are at increased risk for squamous cell carcinoma of the anal canal (SCCAC) and the incidence of SCCAC has increased in the era of HAART (highly active antiretroviral therapy).
  • The aim of this study is to describe the outcome, tolerability, and overall survival (OS) in pts with and without HIV infection treated at Karmanos Cancer Institute, at Wayne State University from 1991 to 2007.
  • We collected data regarding HIV status, demographics (age, gender, race), stage at diagnosis, treatment, response to treatment, toxicity, and survival.
  • HIV (+) pts had significantly better stage (p = 0.011) and less frequent reduced chemotherapy dose (p = 0.001).
  • CONCLUSIONS: HIV (+) pts had better stage, received standard chemotherapy dose more often, and had more frequent XRT dermatitis than HIV (-) pts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962344.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Conroy T, Ducreux M, Lemanski C, Francois E, Giovannini M, Cvitkovic F, Mirabel X, Bouché O, Montoto-Grillot C, Peiffert D: Treatment intensification by induction chemotherapy (ICT) and radiation dose escalation in locally advanced squamous cell anal canal carcinoma (LAAC): Definitive analysis of the intergroup ACCORD 03 trial. J Clin Oncol; 2009 May 20;27(15_suppl):4033

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment intensification by induction chemotherapy (ICT) and radiation dose escalation in locally advanced squamous cell anal canal carcinoma (LAAC): Definitive analysis of the intergroup ACCORD 03 trial.
  • The 4 arms were well balanced concerning the sex-ratio, age, stage, T size and differentiation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961547.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Larbaoui B: Preoperative concomitant chemoradiotherapy with capecitabine in locally advanced rectal carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e15134

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative concomitant chemoradiotherapy with capecitabine in locally advanced rectal carcinoma.
  • : e15134 Background: Preoperative concomitant chemoradiotherapy has shown to improve local control and sphincter preservation with decreased acute toxicity compared with postoperative treatment in locally advanced rectal carcinoma.
  • METHODS: Inclusion criteria: rectal adenocarcinoma <12 cms from anal verge, clinical stage T3-4, adequate renal, hematological and liver function.
  • Clinical stage (determined by CT or RMI): T3: 70% and T4: 30%.
  • Tumor location (from anal verge): < 6 cm in 8pts, >6 cm in 7pts.
  • CONCLUSIONS: Preliminary results show that preoperative concomitant chemoradiotherapy with Capecitabine is an effective regimen with an acceptable safety profile for locally advanced rectal cancer, leading to a high probability of tumor downstaging.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960909.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Eng C, Chang GJ, Das P, Rodriguez-Bigas M, Skibber JM, Qiao W, Rosner GL, Ukegbu LT, Wolff RA, Crane CH: Phase II study of capecitabine and oxaliplatin with concurrent radiation therapy (XELOX-XRT) for squamous cell carcinoma of the anal canal. J Clin Oncol; 2009 May 20;27(15_suppl):4116

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of capecitabine and oxaliplatin with concurrent radiation therapy (XELOX-XRT) for squamous cell carcinoma of the anal canal.
  • : 4116 Background: Definitive therapy for squamous cell carcinoma (SCC) of the anal canal consists of external beam radiotherapy with concurrent 5-fluorouracil and mitomycin C or cisplatin.
  • The purpose of this study was to evaluate the tolerability and efficacy of XELOX-XRT as definitive treatment for anal cancer.
  • METHODS: Patients with histologically proven SCC of the anal canal, AJCC Stage II-IIIB (T<sub>2-4</sub> or N+M<sub>0</sub>), ECOG PS 0-1, HIV<sup>-</sup>, and no prior therapy were eligible for XELOX-based chemoradiotherapy.
  • Therefore, the chemotherapy schedule was modified and only 1 of 9 patients in Group 2 developed grade 3 diarrhea.
  • CONCLUSIONS: The combination of capecitabine, oxaliplatin, and radiation therapy (XELOX-XRT) is effective for locally advanced squamous cell carcinoma of the anal canal.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961220.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Swampillai A, Williams M, Osborne M, Mawdsley S, Hughes R, Harrison M, Glynne-Jones R: A single-center study of the utility of squamous cell carcinoma antigen (SCCAg) levels in epidermoid carcinoma of the anal canal and margin (ECACM) treated with chemoradiation (CRT). J Clin Oncol; 2009 May 20;27(15_suppl):4117

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A single-center study of the utility of squamous cell carcinoma antigen (SCCAg) levels in epidermoid carcinoma of the anal canal and margin (ECACM) treated with chemoradiation (CRT).
  • All 195 were treated with CRT- (50.4Gy in 28 fractions of 1.8 Gy with 5-fluorouracil (5-FU) + mitomycin (MMC).
  • Radiotherapy comprised the schedule of the UK Anal cancer Trial (ACT II).
  • Clinical stage at diagnosis- Tx (6) T1 (28), T2 (80), T3 (65), T4 (16), N0 (126), N+ (66) Nx (3).
  • RESULTS: Mean baseline SCCAg by cT and cN stage were: T1 93 (ng/dl), T2 300, T3 607, T4 882, N0 376, N+ 529 (correlation coeff: T: 0.47, N: 0.33, both p< 0.001).
  • CONCLUSIONS: There is a correlation between T and N stage and baseline SCC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961219.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Ortholan C, Ramaioli A, Peiffert D, Lusinchi A, Romestaing P, Chauveinc L, Touboul E, Peignaux K, Bruna A, de La Roche G, Lagrange JL, Alzieu C, Gerard JP: Anal canal carcinoma: early-stage tumors &lt; or =10 mm (T1 or Tis): therapeutic options and original pattern of local failure after radiotherapy. Int J Radiat Oncol Biol Phys; 2005 Jun 1;62(2):479-85
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal canal carcinoma: early-stage tumors < or =10 mm (T1 or Tis): therapeutic options and original pattern of local failure after radiotherapy.
  • PURPOSE: To investigate the clinical history, management, and pattern of recurrence of very early-stage anal canal cancer in a French retrospective survey.
  • METHODS: The study group consisted of 69 patients with Stage Tis and T1 anal canal carcinoma < or =1 cm treated between 1990 and 2000 (12 were in situ, 57 invasive, 66 Stage N0, and 3 Stage N1).
  • These small anal cancers could be treated by RT using a small volume and moderate dose (40-50 Gy for subclinical lesions and 50-60 Gy for T1).
  • [MeSH-major] Anus Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / physiology. Carcinoma in Situ / pathology. Carcinoma in Situ / radiotherapy. Carcinoma in Situ / surgery. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / radiotherapy. Carcinoma, Transitional Cell / surgery. Chi-Square Distribution. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Radiotherapy Dosage

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15890590.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Koh DM, Dzik-Jurasz A, O'Neill B, Tait D, Husband JE, Brown G: Pelvic phased-array MR imaging of anal carcinoma before and after chemoradiation. Br J Radiol; 2008 Feb;81(962):91-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pelvic phased-array MR imaging of anal carcinoma before and after chemoradiation.
  • The aim of this study was to evaluate the MR findings of anal carcinoma using an external pelvic phased-array coil before and after chemoradiation treatment.
  • 15 patients with carcinoma of the anal canal underwent T(2) weighted and short-tau inversion recovery (STIR) imaging before and after chemoradiation.
  • At pre-treatment imaging, the tumour size and stage, signal intensity and infiltration of adjacent structures were recorded.
  • Pelvic phased-array MR imaging is useful for local staging of anal carcinoma and assessing treatment response.
  • [MeSH-major] Anus Neoplasms / diagnosis. Carcinoma, Basal Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Magnetic Resonance Imaging

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18238920.001).
  • [ISSN] 1748-880X
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


24. Zuo ZG, Song HY, Li J, Xu C, Zhou ZH, Ni SC, Chen SQ: [Clinical application of intersphincteric resection in the anal-preserving operation for ultra-low rectal carcinoma]. Zhonghua Zhong Liu Za Zhi; 2009 Dec;31(12):941-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical application of intersphincteric resection in the anal-preserving operation for ultra-low rectal carcinoma].
  • OBJECTIVE: To investigate the clinical application of intersphincter resection (ISR) combined with total mesorectal excision (TME) and colon-anal anastomosis in the treatment for ultra-low rectal carcinoma.
  • METHODS: To review and analyze retrospectively the data of 34 patients with ultra-low rectal carcinoma (without external anal sphincter involvement) who received treatment of ISR, TME and colon-anal anastomosis.
  • Reconstruction of digestive tract was done by manual colon-anal anastomosis.
  • The pathological types were as follows: 28 cases of adenocarcinoma (11 were well differentiated, 17 moderately differentiated), 1 case of papillary carcinoma and 5 cases of villous adenoma with malignant change.
  • The postoperative pathological stages were: Dukes stage A in 28 cases, stage B in 1 and stage C in 5 cases.
  • CONCLUSION: With strictly grasping indications, radical resection can be attained and anal sphincter preserved by ISR combined with TME and colon-anal anastomosis.
  • [MeSH-major] Adenocarcinoma / surgery. Anal Canal / surgery. Rectal Neoplasms / surgery. Rectum / surgery
  • [MeSH-minor] Adenoma, Villous / pathology. Adenoma, Villous / surgery. Adult. Aged. Aged, 80 and over. Anastomosis, Surgical. Carcinoma, Papillary / pathology. Carcinoma, Papillary / surgery. Female. Follow-Up Studies. Humans. Liver Neoplasms / secondary. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Retrospective Studies. Surgical Wound Dehiscence / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20193339.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] China
  •  go-up   go-down


25. Mullen JT, Rodriguez-Bigas MA, Chang GJ, Barcenas CH, Crane CH, Skibber JM, Feig BW: Results of surgical salvage after failed chemoradiation therapy for epidermoid carcinoma of the anal canal. Ann Surg Oncol; 2007 Feb;14(2):478-83
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of surgical salvage after failed chemoradiation therapy for epidermoid carcinoma of the anal canal.
  • BACKGROUND: The standard treatment for epidermoid carcinoma of the anal canal consists of combined radiation and chemotherapy.
  • Factors that were not found to have an impact on survival included the presence of persistent versus recurrent disease, tumor (T) stage, and margin status of resection.
  • CONCLUSIONS: Long-term survival following salvage surgery for persistent or locally recurrent epidermoid carcinoma of the anal canal can be achieved in the majority of patients.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy. Neoplasm Recurrence, Local / surgery. Neoplasm, Residual / surgery

  • Genetic Alliance. consumer health - Epidermoid Carcinoma.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17103253.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Roohipour R, Patil S, Goodman KA, Minsky BD, Wong WD, Guillem JG, Paty PB, Weiser MR, Neuman HB, Shia J, Schrag D, Temple LK: Squamous-cell carcinoma of the anal canal: predictors of treatment outcome. Dis Colon Rectum; 2008 Feb;51(2):147-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous-cell carcinoma of the anal canal: predictors of treatment outcome.
  • PURPOSE: The incidence of anal canal squamous-cell carcinoma is increasing.
  • METHODS: Using one database, we identified 131 Stages I-III patients treated for primary anal canal squamous-cell carcinoma at our institution from December 1986 to August 2006, with minimum six-month follow-up.
  • RESULTS: Of 131 patients (median age, 58.3 years; median follow-up, 2.9 (range, 0.6-11.2) years), 66 percent were females, 43.5 percent were Stage II, and 11 (8 percent) were HIV-positive.
  • Almost all patients undergoing radiotherapy (96.7 percent, 118/122) also had chemotherapy: 118 (100 percent, Stages I-III) had concurrent chemotherapy: (98 (83.8 percent) mitomycin/5-fluorouracil, 12 (10.2 percent) cisplatin/5-fluorouracil, 8 (6.8 percent) 5-fluorouracil alone); 35 of 46 (76 percent) Stage III patients received induction chemotherapy (34 (97.1 percent) cisplatin/5-fluorouracil, 1 (2.8 percent) 5-fluorouracil alone).
  • Many (44 percent Stages I/II, 48.9 percent Stage III) required dose adjustments.
  • Bivariate analyses demonstrated that T stage (P=0.0019), completion of radiotherapy, and total radiotherapy dose (P=0.03) were all significantly associated with treatment failure.
  • On multivariate analyses, disease stage (P=0.05) and completion of radiotherapy (P=0.01) remained significant predictors of relapse-free survival.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Dis Colon Rectum. 2008 May;51(5):620
  • (PMID = 18180997.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


27. Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS, Halverson AL: Squamous cell carcinoma of the anal canal: utilization and outcomes of recommended treatment in the United States. Ann Surg Oncol; 2008 Jul;15(7):1948-58
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma of the anal canal: utilization and outcomes of recommended treatment in the United States.
  • BACKGROUND: Over the past two decades, recommended treatment for squamous cell carcinoma of the anal canal has shifted from surgery to primary chemoradiation.
  • METHODS: From the National Cancer Data Base (1985-2005), 38,882 patients with anal canal cancer were identified.
  • Patients were significantly less likely to receive guideline treatment if male, older, black or Hispanic, more severe comorbidities, or Stage I (vs Stage II or III).
  • [MeSH-major] Anus Neoplasms / therapy. Neoplasms, Squamous Cell / therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18414951.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


28. Das P, Bhatia S, Eng C, Ajani JA, Skibber JM, Rodriguez-Bigas MA, Chang GJ, Bhosale P, Delclos ME, Krishnan S, Janjan NA, Crane CH: Predictors and patterns of recurrence after definitive chemoradiation for anal cancer. Int J Radiat Oncol Biol Phys; 2007 Jul 1;68(3):794-800
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors and patterns of recurrence after definitive chemoradiation for anal cancer.
  • PURPOSE: To evaluate patterns of locoregional failure, and predictors of recurrence and survival in patients treated with chemoradiation for anal cancer.
  • METHODS AND MATERIALS: Between September 1992 and August 2004, 167 patients with nonmetastatic squamous cell anal carcinoma were treated with definitive chemoradiation.
  • Multivariate analysis showed that higher T stage and N stage independently predicted for a higher rate of locoregional failure; higher N stage and basaloid subtype independently predicted for a higher rate of distant metastasis; and higher N stage and positive human immunodeficiency virus status independently predicted for a lower rate of overall survival.
  • Among the patients who had locoregional failure, 18 (75%) had failure involving the anus or rectum, 5 (21%) had other pelvic recurrences, and 1 (4%) had inguinal recurrence.
  • The majority of locoregional failures involve the anus and rectum, whereas inguinal recurrences occur rarely.
  • [MeSH-major] Anus Neoplasms / mortality. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / therapy. Chemotherapy, Adjuvant / mortality. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / prevention & control. Radiotherapy, Adjuvant / mortality

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17379452.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Bilimoria KY, Bentrem DJ, Rock CE, Stewart AK, Ko CY, Halverson A: Outcomes and prognostic factors for squamous-cell carcinoma of the anal canal: analysis of patients from the National Cancer Data Base. Dis Colon Rectum; 2009 Apr;52(4):624-31
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes and prognostic factors for squamous-cell carcinoma of the anal canal: analysis of patients from the National Cancer Data Base.
  • PURPOSE: The objective of this study was to assess survival and prognostic factors for anal carcinoma in the population.
  • METHODS: Patients with squamous-cell carcinoma of the anal canal were identified from the National Cancer Data Base (1985-2000).
  • Concordance was calculated to assess agreement between American Joint Committee on Cancer stage and actual outcome.
  • RESULTS: Nineteen thousand one hundred ninety-nine patients with anal carcinoma were identified (Stage I, 25.3 percent; Stage II, 51.8 percent; Stage III, 17.1 percent; Stage IV, 5.7 percent).
  • The American Joint Committee on Cancer (6th edition) staging system provided good survival discrimination by stage: I, 69.5 percent; II, 59.0 percent; III, 40.6 percent; and IV, 18.7 percent (concordance index, 0.663).
  • On multivariable analysis, patients with anal carcinoma had a higher risk of death if they were male, >or=65 years old, black, living in lower median incomes areas, and had more advanced T stage tumors, nodal or distant metastases, or poorly differentiated cancers (P < 0.0001).
  • CONCLUSION: Although tumor characteristics and staging affect prognosis, patient factors, such as gender, race, and socioeconomic status, are also important prognostic factors for squamous-cell carcinoma of the anal canal.
  • [MeSH-major] Anus Neoplasms / mortality. Carcinoma, Squamous Cell / mortality

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19404066.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


30. Nguyen BT, Joon DL, Khoo V, Quong G, Chao M, Wada M, Joon ML, See A, Feigen M, Rykers K, Kai C, Zupan E, Scott A: Assessing the impact of FDG-PET in the management of anal cancer. Radiother Oncol; 2008 Jun;87(3):376-82
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessing the impact of FDG-PET in the management of anal cancer.
  • PURPOSE: To assess the utility of FDG-PET in anal cancer for staging and impact on radiotherapy planning (RTP), response and detection of recurrent disease.
  • METHODS AND MATERIALS: Fifty histopathological anal cancer patients were reviewed between 1996 and 2006.
  • RESULTS: The non-PET staging was Stage I(8), Stage II(18), Stage III(22), and Stage IV(2)s.
  • CONCLUSIONS: Anal cancer is FDG-PET avid.
  • PET can aid in anal cancer staging and identification of residual disease, recurrent/metastatic disease but warrants further prospective studies.
  • [MeSH-major] Anus Neoplasms / radionuclide imaging. Carcinoma, Squamous Cell / radionuclide imaging. Fluorodeoxyglucose F18. Positron-Emission Tomography. Radiopharmaceuticals

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18453023.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


31. Rabbani AN, Zlotecki RA, Kirwan J, George TJ Jr, Morris CG, Rout WR, Mendenhall WM: Definitive radiotherapy for squamous cell carcinoma of the anal canal. Am J Clin Oncol; 2010 Feb;33(1):47-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Definitive radiotherapy for squamous cell carcinoma of the anal canal.
  • PURPOSE: To review the outcomes of definitive radiotherapy (RT) alone or combined with chemotherapy (CT) in the treatment of squamous cell carcinoma of the anal canal.
  • Distribution according to T stage was: T1, 11 (16%); T2, 29 (42%); T3, 21 (30%); and T4, 8 (12%).
  • Distribution according to N stage was: N0, 53 (77%); N1, 3 (4%); N2, 7 (10%); and N3, 6 (9%).
  • The 5-year cause-specific and overall survival rates were: stage I, 100% and 64%; stage II, 86% and 70%; stage III, 80% and 76%; and overall, 87% and 71%, respectively.
  • [MeSH-major] Anal Canal / radiation effects. Antineoplastic Agents / therapeutic use. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Neoplasm Recurrence, Local / diagnosis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19704368.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


32. Kagawa R, Yamaguchi T, Furuta R: Histological features of human papilloma virus 16 and its association with the development and progression of anal squamous cell carcinoma. Surg Today; 2006;36(10):885-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histological features of human papilloma virus 16 and its association with the development and progression of anal squamous cell carcinoma.
  • PURPOSE: To investigate the development of anal squamous cell carcinoma (SCC) and the expression patterns of human papillomavirus (HPV).
  • The expression patterns of HPV in the cancer cell nuclei was investigated by in situ hybridization (ISH) using HPV probes.
  • RESULTS: Amplification of DMD genes was confirmed in 8 of 20 patients with anal SCC, suggesting that tumor DNA was preserved in these patients.
  • In two patients with carcinoma in situ (CIS), the cancer cells showed only a diffuse pattern (DP), and in two patients with invasive cancer, the cancer cell showed only an oligo-dot pattern (OP).
  • In one patient with lesions ranging from CIS to invasive cancer, the histologic features varied in each area, from DP to OP.
  • CONCLUSIONS: These findings show that HPV16 infection is closely involved in the development of anal SCC and suggest that the change in the genome occurs at the stage of microinvasive cancer.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. DNA, Viral / genetics. Human papillomavirus 16 / genetics. Papillomavirus Infections / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16998682.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


33. Tajima Y, Ishibashi K, Gonda T, Miyazaki T, Nakada H, Takahashi T, Ishida H: [Squamous cell carcinoma of the anal canal showing complete response following chemoradiotherapy--a case report]. Gan To Kagaku Ryoho; 2007 Nov;34(12):2050-2
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Squamous cell carcinoma of the anal canal showing complete response following chemoradiotherapy--a case report].
  • We report a case of squamous cell carcinoma of the anal canal which showed complete response following chemoradiotherapy.
  • A 54-year-old woman was diagnosed as having squamous cell carcinoma of the anal canal (T2N0M0 stage II).
  • This case suggests that we should take measures to prevent distant metastases in the treatment of squamous cell carcinoma of the anal canal.
  • [MeSH-major] Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18219895.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


34. Sueda K, Ikenaga M, Miyazaki M, Yasui M, Mishima H, Tsujie M, Omiya H, Miyamoto A, Hirao M, Takami K, Fujitani K, Nakamori S, Yoshida K, Tsujinaka T: [A case of squamous cell carcinoma of the anal cancer with associated human immunodeficiency virus]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2656-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of squamous cell carcinoma of the anal cancer with associated human immunodeficiency virus].
  • He presented with an anal tumor with bilateral inguinal nodal metastasis and pain in the anus; the tumor was diagnosed as stage IIIb (cA1N2M0).
  • We report a case of squamous cell carcinoma of the anus with associated HIV infection.
  • [MeSH-major] Anus Neoplasms / complications. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / therapy. HIV Seropositivity / complications


35. Wright JL, Patil SM, Temple LK, Minsky BD, Saltz LB, Goodman KA: Squamous cell carcinoma of the anal canal: patterns and predictors of failure and implications for intensity-modulated radiation treatment planning. Int J Radiat Oncol Biol Phys; 2010 Nov 15;78(4):1064-72
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma of the anal canal: patterns and predictors of failure and implications for intensity-modulated radiation treatment planning.
  • PURPOSE: Intensity-modulated radiation treatment (IMRT) is increasingly used in the treatment of squamous cell carcinoma of the anal canal (SCCAC).
  • In patients with advanced tumor or nodal stage, common iliac nodes should also be included in the CTV.
  • [MeSH-major] Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Radiotherapy Planning, Computer-Assisted / methods. Radiotherapy, Intensity-Modulated / methods. Tumor Burden

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20350793.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


36. Hauerstock D, Ennis RD, Grossbard M, Evans A: Efficacy and toxicity of chemoradiation in the treatment of HIV-associated anal cancer. Clin Colorectal Cancer; 2010 Oct;9(4):238-42
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and toxicity of chemoradiation in the treatment of HIV-associated anal cancer.
  • PURPOSE: The purpose of this retrospective study is to determine the results and the toxicity of concurrent chemoradiation for squamous cell carcinoma of the anal canal in HIV-positive patients treated at a single institution.
  • PATIENTS AND METHODS: HIV-positive patients with squamous cell carcinoma of the canal treated at Continuum Cancer Centers-affiliated hospitals were identified from tumor registries.
  • We reviewed hospital and treatment charts to gather data relating to demographics, HIV status including cluster of differentiation 4 (CD4) count and viral load, tumor stage, radiation and chemotherapy treatment, toxicity and local control, and survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy. HIV Infections / complications. Radiotherapy, Conformal


37. Crowley C, Winship AZ, Hawkins MA, Morris SL, Leslie MD: Size does matter: can we reduce the radiotherapy field size for selected cases of anal canal cancer undergoing chemoradiation? Clin Oncol (R Coll Radiol); 2009 Jun;21(5):376-9
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Size does matter: can we reduce the radiotherapy field size for selected cases of anal canal cancer undergoing chemoradiation?
  • AIMS: Chemoradiation is the standard of care for the treatment of anal canal cancer, with surgery reserved for salvage.
  • MATERIALS AND METHODS: Between August 1998 and August 2004, 30 patients with biopsy-proven squamous cell anal canal cancer were treated with chemoradiation using one phase of treatment throughout.
  • CONCLUSIONS: This single-centre retrospective study supports the treatment for selected cases of anal canal cancer with smaller than standard radiation fields, avoiding prophylactic inguinal nodal irradiation.
  • In future studies we would suggest that consideration is given as to whether omission of prophylactic inguinal nodal irradiation for early stage tumours should be explored.
  • [MeSH-major] Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Lymphatic Irradiation. Radiation Injuries / prevention & control
  • [MeSH-minor] Aged. Aged, 80 and over. Combined Modality Therapy / adverse effects. Female. Humans. Inguinal Canal. Male. Middle Aged. Patient Compliance. Pelvis. Radiation Dosage. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19282157.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


38. de Bree E, van Ruth S, Dewit LG, Zoetmulder FA: High risk of colostomy with primary radiotherapy for anal cancer. Ann Surg Oncol; 2007 Jan;14(1):100-8
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High risk of colostomy with primary radiotherapy for anal cancer.
  • BACKGROUND: Radiotherapy (RT) has become the primary treatment of choice for anal cancer in an effort to avoid colostomy.
  • Early stage disease, low T-score and absence of infiltration in adjacent organs were associated with a reduced need for colostomy in univariate analysis.
  • CONCLUSIONS: In approximately one-third of the patients treated by anal sphincter saving management with curative aimed primary RT, the creation of a colostomy appeared to be necessary for RT complications and local treatment failure.
  • Therefore, patients should be well informed regarding the considerable risk of need for colostomy after RT for anal cancer.
  • [MeSH-major] Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Colostomy

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17066231.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Jeffreys M, Rachet B, McDowell S, Habib AG, Lepage C, Coleman MP: Survival from rectal and anal cancers in England and Wales, 1986-2001. Eur J Cancer; 2006 Jul;42(10):1434-40

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival from rectal and anal cancers in England and Wales, 1986-2001.
  • The aim of this study was to investigate the effects of tumour and patient characteristics on trends in the survival of patients with cancer of the anus or rectum in England and Wales.
  • The results showed that 5-year relative survival was higher in women, younger patients and more affluent patients, and higher for anal cancer than rectal cancer.
  • The trend was more marked in younger and more affluent patients, and for adenocarcinoma and epidermoid carcinoma than for tumours with other morphology.
  • It is concluded that improvements in survival may reflect improvements in disease stage, diagnostic technique or treatment.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Anus Neoplasms / mortality. England / epidemiology. Female. Humans. Middle Aged. Survival Analysis. Wales / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16600590.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


40. Fallai C, Cerrotta A, Valvo F, Badii D, Olmi P: Anal carcinoma of the elderly treated with radiotherapy alone or with concomitant radio-chemotherapy. Crit Rev Oncol Hematol; 2007 Mar;61(3):261-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal carcinoma of the elderly treated with radiotherapy alone or with concomitant radio-chemotherapy.
  • PURPOSE: To analyse the results achieved with radio-chemotherapy (RTCT) or radiotherapy alone (RT) in elderly patients (pts) affected with squamous cell anal cancer.
  • There were 9 stage I, 29 stage II, 11 stage IIIa and 13 stage IIIb.
  • RESULTS: Stage II fared significantly better than stage III in terms of locoregional control (LRC) but not overall survival (OS).
  • [MeSH-major] Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17085056.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


41. Dwyer MK, Gebski VJ, Jayamohan J: The bottom line: outcomes after conservation treatment in anal cancer. Australas Radiol; 2006 Feb;50(1):46-51
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The bottom line: outcomes after conservation treatment in anal cancer.
  • At the Department of Radiation Oncology, Westmead Hospital, between 1980 and 2000, 60 patients with squamous cell carcinoma of anal canal or margin (including 15 with Stage IIIA or IIIB) were treated radically; 55 received chemoradiation (89% were prescribed mitomycin C and 5-fluorouracil).
  • Most patients with anal cancer can expect to retain a functional sphincter after chemoradiation/radiation.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16499727.001).
  • [ISSN] 0004-8461
  • [Journal-full-title] Australasian radiology
  • [ISO-abbreviation] Australas Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


42. Helpap B, Egevad L: Correlation of modified Gleason grading with pT stage of prostatic carcinoma after radical prostatectomy. Anal Quant Cytol Histol; 2008 Feb;30(1):1-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of modified Gleason grading with pT stage of prostatic carcinoma after radical prostatectomy.
  • OBJECTIVE: To study the correlation between modified Gleason score (GS) and pT stage of radical prostatectomy (RP) specimens.
  • Both variants of GS correlated with pathologic stage.
  • Stage pT2 tumors were assigned a GS of 3-6 less often with modified grading than with conventional grading (29% and 84%, respectively).
  • The only significant difference of stage distribution between conventional and modified GS was for GS 7, where pT2 was the most common stage with modified grading (54%) and pT3 was most common with conventional grading (67%).
  • Of GS 3 + 4 = 7a tumors, 95% were stage pT2, while 79% of GS 4 + 3 = 7b tumors were stage pT3-4.
  • CONCLUSION: The stage distribution of modified GSs of RP specimens differs from that of conventional GSs, but a good correlation exists between grade and pT stage.
  • Notably, GS 4 + 3 = 7b was more often associated with high stage than was GS 3 + 4 = 7a.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18459581.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Otto SD, Lee L, Buhr HJ, Frericks B, Höcht S, Kroesen AJ: Staging anal cancer: prospective comparison of transanal endoscopic ultrasound and magnetic resonance imaging. J Gastrointest Surg; 2009 Jul;13(7):1292-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Staging anal cancer: prospective comparison of transanal endoscopic ultrasound and magnetic resonance imaging.
  • PURPOSE: The staging of anal cancer is extremely important for therapy and prognosis.
  • METHODS: Forty-five anal cancer patients underwent endoscopic ultrasound and magnetic resonance imaging.
  • For six patients who were operated upon because of tumor progression, the results were evaluated against the histological tumor stage.
  • Cancer patients were correctly identified with 100% sensitivity (45/45) by endoscopic ultrasound and with 88.9% (40/45) sensitivity by magnetic resonance imaging.
  • In the six operated patients, T stage was correctly assessed in four of six patients by endoscopic ultrasound and in three of six patients by magnetic resonance imaging.
  • [MeSH-major] Anus Neoplasms / pathology. Anus Neoplasms / ultrasonography. Endosonography. Magnetic Resonance Imaging. Neoplasm Staging / methods
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / ultrasonography. Adult. Aged. Aged, 80 and over. Biopsy, Needle. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / ultrasonography. Cohort Studies. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Invasiveness / ultrasonography. Prospective Studies. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19365694.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Oehler-Jänne C, Seifert B, Lütolf UM, Studer G, Glanzmann C, Ciernik IF: Clinical outcome after treatment with a brachytherapy boost versus external beam boost for anal carcinoma. Brachytherapy; 2007 Jul-Sep;6(3):218-26
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcome after treatment with a brachytherapy boost versus external beam boost for anal carcinoma.
  • PURPOSE: To evaluate the outcome after definitive whole pelvis external beam radiotherapy (EBRT) followed by brachytherapy (BT) boost after treatment break vs. external beam boost without break in the treatment of anal carcinoma.
  • METHODS AND MATERIALS: Eighty-one consecutive patients with invasive anal carcinoma were analyzed retrospectively.
  • Concomitant chemotherapy (CT) with mitomycin C was applied during whole pelvis EBRT depending on tumor stage.
  • Pattern of care, local disease control (LC), cancer-specific survival (CSS), overall survival (OS), toxicity, and quality of life (QOL) were assessed.
  • In early stage tumors, (192)Ir-HDR BT boost with CT resulted in a 5-year LC and CSS of 100%.
  • In all patients, BT boost did not result in improved LC, OS, and CSS compared with EBRT boost, despite stage and treatment bias favoring small tumors to be treated with BT.
  • BT boost is most beneficial in early stage tumors but the advantage of BT seems to be limited due to its invasiveness, doctor dependence, and logistic circumstances.
  • [MeSH-major] Anus Neoplasms / radiotherapy. Brachytherapy / instrumentation. Carcinoma / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17681244.001).
  • [ISSN] 1538-4721
  • [Journal-full-title] Brachytherapy
  • [ISO-abbreviation] Brachytherapy
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


45. Martellucci J, Naldini G, Colosimo C, Cionini L, Rossi M: Accuracy of endoanal ultrasound in the follow-up assessment for squamous cell carcinoma of the anal canal treated with radiochemotherapy. Surg Endosc; 2009 May;23(5):1054-7
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accuracy of endoanal ultrasound in the follow-up assessment for squamous cell carcinoma of the anal canal treated with radiochemotherapy.
  • BACKGROUND: Radiochemotherapy has largely replaced surgery in the treatment for squamous cell cancer of the anal canal.
  • Transanal ultrasonography is well documented as an important investigation method in the management of anal carcinoma.
  • METHODS: The study enrolled 16 consecutive patients with biopsy-proven squamous carcinoma of the anal canal between 2003 and 2006.
  • RESULTS: Nine patients had stage uT2 disease; none had uT3 disease; and seven had uT4 disease.
  • CONCLUSIONS: Endoanal ultrasound is a safe and effective method for evaluating and following anal cancer before and after treatment.
  • Experience and evaluation during the period of the ultrasonographic abnormalities could give a clear idea concerning the evolution of the anal tumors treated with radiochemotherapy.
  • [MeSH-major] Anus Neoplasms / ultrasonography. Carcinoma, Squamous Cell / ultrasonography. Endosonography

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18813993.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


46. Blazy A, Hennequin C, Gornet JM, Furco A, Gérard L, Lémann M, Maylin C: Anal carcinomas in HIV-positive patients: high-dose chemoradiotherapy is feasible in the era of highly active antiretroviral therapy. Dis Colon Rectum; 2005 Jun;48(6):1176-81
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal carcinomas in HIV-positive patients: high-dose chemoradiotherapy is feasible in the era of highly active antiretroviral therapy.
  • BACKGROUND: Anal carcinoma, a common disease in HIV-positive patients, is usually treated with chemoradiotherapy.
  • We report our experience of treating anal carcinoma in the era of new antiviral drugs.
  • PATIENTS AND METHODS: Between 1997 and 2001, nine men on highly active antiretroviral therapies with good immune status before chemoradiotherapy received concomitant chemoradiotherapy consisting of 5-fluorouracil and cisplatinum, and high-dose radiotherapy (60-70 Gy) for anal carcinoma.
  • Six cancers were Stage I, two were Stage II, and one was Stage III.
  • Among them, four had no or minor anal function impairment at the last follow-up visit.
  • CONCLUSION: High-dose chemoradiotherapy for anal carcinomas is feasible with low toxicity in HIV-positive patients treated with highly active antiretroviral therapies.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy. Cisplatin / administration & dosage. Fluorouracil / administration & dosage. HIV Infections / complications

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15906137.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents; 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


47. Ferrigno R, Nakamura RA, Dos Santos Novaes PE, Pellizzon AC, Maia MA, Fogarolli RC, Salvajoli JV, Filho WJ, Lopes A: Radiochemotherapy in the conservative treatment of anal canal carcinoma: retrospective analysis of results and radiation dose effectiveness. Int J Radiat Oncol Biol Phys; 2005 Mar 15;61(4):1136-42
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiochemotherapy in the conservative treatment of anal canal carcinoma: retrospective analysis of results and radiation dose effectiveness.
  • PURPOSE: This retrospective analysis reports the results on patients with anal canal carcinoma treated by combined radiotherapy and chemotherapy.
  • METHODS AND MATERIALS: Between March 1993 and December 2001, 43 patients with anal canal carcinoma were treated with radiochemotherapy at the Hospital do Cancer A.C. Camargo.
  • Stage distribution was as follows: I, 3 (7%); II, 23 (53.5%); IIIA, 8 (18.6%); and IIIB, 9 (21%).
  • Patient's age, tumor stage, overall treatment time, and RT dose at primary tumor were variables analyzed for survival and local control.
  • Overall survival according to clinical stage was as follows: I, 100%; II, 82%; IIIA, 73%; and IIIB, 18% (p = 0.0049).
  • CONCLUSIONS: This analysis suggests that the treatment scheme employed was effective for anal sphincter preservation and local control; however, the incidence of distant metastases was relatively high.
  • The clinical stage was the main prognostic factor for overall survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15752894.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


48. Nakagawa S, Amano M, Yamashita S, Nishikawa Y, Higaki N, Hayashida H, Niinobu T, Yoshioka Y, Sakon M: [A case of effective chemoradiation therapy against anal fistula carcinoma recurred 10 years after surgery]. Gan To Kagaku Ryoho; 2006 Nov;33(12):1977-9
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of effective chemoradiation therapy against anal fistula carcinoma recurred 10 years after surgery].
  • A male in his eighties underwent abdominoperineal resection under the diagnosis of adenocarcinoma associated with anal fistula (P0, H0, n (-), A1, stage II, ly0, v0).
  • [MeSH-major] Adenocarcinoma / therapy. Anus Neoplasms / therapy. Rectal Fistula / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17212165.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 1-UFT protocol
  •  go-up   go-down


49. Renehan AG, Saunders MP, Schofield PF, O'Dwyer ST: Patterns of local disease failure and outcome after salvage surgery in patients with anal cancer. Br J Surg; 2005 May;92(5):605-14
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of local disease failure and outcome after salvage surgery in patients with anal cancer.
  • BACKGROUND: Salvage surgery for anal cancer is usually reserved for local disease failure, but issues relating to the prediction of local failure and surgical outcome are ill defined.
  • METHODS: Between 1988 and 2000, 254 patients with non-metastatic anal epidermoid carcinoma were treated at a regional cancer centre with radiotherapy (n = 127) or chemoradiotherapy (n = 127).
  • Increasing age (P < 0.001, Cox model), total radiation dose (P = 0.004) and tumour stage (P = 0.010) were independent predictors of local failure.
  • CONCLUSION: In the management of anal cancer, local disease failure is a major clinical problem requiring early detection followed by radical surgery, often accompanied by plastic reconstruction.
  • By implication, these factors favour the centralization of treatment for this uncommon cancer to a multidisciplinary oncology team.
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Salvage Therapy / methods

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
  • (PMID = 15739215.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


50. Kiran RP, Pokala N, Rottoli M, Fazio VW: Is survival reduced for patients with anal cancer requiring surgery after failure of radiation? Analysis from a population study over two decades. Am Surg; 2009 Feb;75(2):163-8
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is survival reduced for patients with anal cancer requiring surgery after failure of radiation? Analysis from a population study over two decades.
  • Chemoradiotherapy is the standard treatment for anal cancer.
  • From a prospective population-based database on radiation and surgical therapy, we compare outcomes for patients with anal cancer undergoing rectal resection after radiation with patients undergoing radiation alone.
  • Patients undergoing surgical resection of the rectum after initial radiation (SRT) for squamous cell carcinoma of the anus, anal canal, cloacogenic zone, and overlapping lesions of the rectum and anal canal from 1983 to 2002 were identified from the Surveillance, Epidemiology and End Results database.
  • SRT had more patients with regional stage of disease (66.7 vs 42.4%, P = 0.001).
  • For patients with localized stage, survival for SRT and RT was similar (105 vs 98 months, P = 0.7).
  • For patients with regional stage, survival for SRT and RT was similar (95 vs 83 months, P = 0.6).
  • [MeSH-major] Anus Neoplasms / mortality. Anus Neoplasms / surgery. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / surgery

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19280811.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Zuo ZG, Song HY, Xu C, Li J, Ni SC, Chen SQ: [Combination of trans-anal intersphincteric resection and trans-abdominal total mesorectal excision for anus-retained ultra-low rectal tumors]. Zhonghua Wai Ke Za Zhi; 2009 Jul 1;47(13):988-91

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Combination of trans-anal intersphincteric resection and trans-abdominal total mesorectal excision for anus-retained ultra-low rectal tumors].
  • OBJECTIVE: To study the combination of trans-anal intersphincteric resection and transabdominal total mesorectal excision for anus-retained ultra-low rectal tumors.
  • METHODS: Clinical data of 34 ultra-low rectal tumor patients without external anal sphincter involved, who underwent the combination surgery, were retrospectively analyzed.
  • For pathological types, there were 23 cases of adenocarcinoma (9 well differentiated and 14 moderately differentiated), 1 papillary carcinoma, 2 rectal stromal tumor, 5 rectal villous adenoma with neoplasia and 3 giant villous adenoma.
  • For pathological stages, there were 18 cases at stage pTNM I, 5 at IIA, 1 at IIB, 4 at IIIA, 1 at III and for T grading, there were 15 cases at stage T1, 5 at T2, 8 at T3, 1 at T4.
  • Because of the dysfunction of bowel control, bowel frequency varied from 3 to 12 in the early stage after operation, but with the recovery of anus function, bowel frequency decreased and ranged form 1 to 5 times a day and the time of formed bowel control could be more than 5 min in 6-12 months after operation.
  • However, patients underwent total resection of internal anal sphincter still suffered from incontinence of loose stool after 1 year.
  • CONCLUSION: The combination of trans-anal ISR and trans-abdominal TME for anus-retained ultra low rectal tumor is not only coincident with radical tumor principle but also retains the function of anus, on the premise of the strict indication.
  • [MeSH-major] Anal Canal / surgery. Mesentery / surgery. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19957808.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


52. Widder J, Kastenberger R, Fercher E, Schmid R, Langendijk JA, Dobrowsky W, Pötter R: Radiation dose associated with local control in advanced anal cancer: retrospective analysis of 129 patients. Radiother Oncol; 2008 Jun;87(3):367-75
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation dose associated with local control in advanced anal cancer: retrospective analysis of 129 patients.
  • BACKGROUND AND PURPOSE: To retrospectively analyse a large consecutive cohort of patients with anal cancer for treatment-related factors influencing local control and survival.
  • MATERIALS AND METHODS: All patients referred for primary radiotherapy at Medical University of Vienna in 1990-2002 with anal canal carcinoma without distant metastases were analysed.
  • RESULTS: Median age was 67 years (n=129), the UICC stage distribution was 15%, 58%, and 27% for stages I, II, and III, respectively.
  • Stage and age were significant factors for overall and colostomy-free-survival, N-stage for disease-free-survival.
  • Shorter overall treatment time favoured local control in stage T1-2 (p=.015), higher total radiation dose and female gender were associated with improved local control in T3-4 tumours (p=.021).
  • CONCLUSIONS: These results support potential improvement of anal cancer treatment by studying advanced technology such as IMRT, making it possible to tailor high-dose regions.
  • [MeSH-major] Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / radiotherapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18501453.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


53. Chen Y, Lim BK, Hashim OH: Different altered stage correlative expression of high abundance acute-phase proteins in sera of patients with epithelial ovarian carcinoma. J Hematol Oncol; 2009;2:37
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Different altered stage correlative expression of high abundance acute-phase proteins in sera of patients with epithelial ovarian carcinoma.
  • BACKGROUND: The general enhanced expression of alpha1-antichymotrypsin (ACT), clusterin (CLU), alpha1-antitrypsin (AAT), haptoglobin beta-chain (HAP), and leucine rich glycoprotein (LRG) in the sera of patients with epithelial ovarian carcinoma (EOCa) was recently reported.
  • In the present study, we compared the expression of the serum acute-phase proteins (APPs) in the patients according to their stages of cancer.
  • RESULTS: Different altered stage correlative expression of the high abundance serum APPs was demonstrated in sera of the patients studied.
  • While the expression of ACT, HAP and AAT appeared to demonstrate positive correlation with the three initial stages of the cancer, inverse correlation was apparently detected in the expression of LRG and CLU.
  • For patients who were diagnosed with stage IV of the cancer, expression of the serum APPs did not conform to the altered progression changes.
  • [MeSH-major] Acute-Phase Proteins / metabolism. Carcinoma in Situ / blood. Ovarian Neoplasms / blood

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17039-44 [15572443.001]
  • [Cites] Gene Ther. 1999 Sep;6(9):1512-9 [10490760.001]
  • [Cites] J Proteome Res. 2005 Sep-Oct;4(5):1742-51 [16212428.001]
  • [Cites] Exp Oncol. 2005 Sep;27(3):233-7 [16244588.001]
  • [Cites] Proteomics. 2005 Nov;5(16):4287-95 [16254924.001]
  • [Cites] J Med Invest. 2006 Feb;53(1-2):20-8 [16537992.001]
  • [Cites] Proteomics. 2006 Jul;6(13):3938-48 [16767791.001]
  • [Cites] Neoplasma. 2007;54(1):46-50 [17203891.001]
  • [Cites] Neoplasia. 2007 Jan;9(1):1-7 [17325738.001]
  • [Cites] Front Biosci. 2007;12:2821-35 [17485262.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Jun 1;852(1-2):257-67 [17303479.001]
  • [Cites] Electrophoresis. 2007 Jun;28(12):1989-96 [17503403.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Sep;16(9):1845-51 [17855704.001]
  • [Cites] Proteomics. 2007 Dec;7(23):4292-302 [17963278.001]
  • [Cites] Electrophoresis. 2008 Jun;29(12):2645-50 [18494030.001]
  • [Cites] Eur J Gynaecol Oncol. 2008;29(6):617-9 [19115690.001]
  • [Cites] Cancer Res. 2000 Jan 1;60(1):170-6 [10646870.001]
  • [Cites] Int J Gynecol Cancer. 2002 Jul-Aug;12(4):372-5 [12144685.001]
  • [Cites] Technol Cancer Res Treat. 2002 Aug;1(4):263-72 [12625785.001]
  • [Cites] Urology. 2003 Nov;62(5 Suppl 1):27-33 [14607215.001]
  • [Cites] Anticancer Res. 2004 Jan-Feb;24(1):241-7 [15015603.001]
  • [Cites] Ann N Y Acad Sci. 2004 Jun;1019:206-10 [15247015.001]
  • [Cites] Electrophoresis. 2004 Jul;25(14):2392-401 [15274022.001]
  • [Cites] N Engl J Med. 1983 Oct 13;309(15):883-7 [6310399.001]
  • [Cites] Electrophoresis. 1988 Jan;9(1):28-32 [2466645.001]
  • [Cites] Hum Reprod. 1989 Jan;4(1):1-12 [2651469.001]
  • [Cites] J Clin Lab Anal. 1995;9(2):123-8 [7536238.001]
  • [Cites] Anal Chem. 1996 Mar 1;68(5):850-8 [8779443.001]
  • [Cites] Electrophoresis. 1996 Mar;17(3):612-6 [8740187.001]
  • [Cites] Kidney Int. 1998 Jun;53(6):1647-53 [9607196.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1110-8 [15709178.001]
  • (PMID = 19709441.001).
  • [ISSN] 1756-8722
  • [Journal-full-title] Journal of hematology & oncology
  • [ISO-abbreviation] J Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Acute-Phase Proteins
  • [Other-IDs] NLM/ PMC2739531
  •  go-up   go-down


54. Goh V, Gollub FK, Liaw J, Wellsted D, Przybytniak I, Padhani AR, Glynne-Jones R: Magnetic resonance imaging assessment of squamous cell carcinoma of the anal canal before and after chemoradiation: can MRI predict for eventual clinical outcome? Int J Radiat Oncol Biol Phys; 2010 Nov 1;78(3):715-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging assessment of squamous cell carcinoma of the anal canal before and after chemoradiation: can MRI predict for eventual clinical outcome?
  • PURPOSE: To describe the MRI appearances of squamous cell carcinoma of the anal canal before and after chemoradiation and to assess whether MRI features predict for clinical outcome.
  • METHODS AND MATERIALS: Thirty-five patients (15 male, 20 female; mean age 60.8 years) with histologically proven squamous cell cancer of the anal canal underwent MRI before and 6-8 weeks after definitive chemoradiation.
  • Images were reviewed retrospectively by two radiologists in consensus blinded to clinical outcome: tumor size, signal intensity, extent, and TNM stage were recorded.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. Magnetic Resonance Imaging
  • [MeSH-minor] Anal Canal / pathology. Analysis of Variance. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Retrospective Studies. Treatment Outcome. Tumor Burden

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20171812.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Selvindos PB, Ho YH: Multimedia article. Laparoscopic ultralow anterior resection with colonic J-pouch-anal anastomosis. Dis Colon Rectum; 2008 Nov;51(11):1710-1

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimedia article. Laparoscopic ultralow anterior resection with colonic J-pouch-anal anastomosis.
  • PURPOSE: Optimal treatment of mid to distal rectal cancers includes total mesorectal excision for oncologic clearance and, where reanastomosis is feasible, a colonic J-pouch-anal anastomosis improves bowel function.
  • Bowel continuity was restored by an intracoporeal double-cross stapled colonic J-pouch-anal anastomosis, but where not possible a coloplasty with pull-through handsewn coloanal anastomosis was performed.
  • The indications were adenocarcinoma (n = 51), squamous-cell carcinoma of rectum (n = 1), dermoid tumor of mesorectum (n = 1), large villous adenoma (n = 1), and carcinoid with local lymph node metastases (n = 1).
  • The adenocarcinomas were a median distance of 6 (3-12) cm from the anal verge.
  • The histologic grading or the adenocarcinoma patients were: Stage I, n = 14; Stage II, n = 23; Stage III, n = 11; Stage IV, n = 3.
  • The level of the coloanal anastomosis was a median 3.5 (0-4.5) cm from the anal verge; a coloanal pull-through anastomosis was required in one patient who had a distal cancer.
  • Four other patients had smaller pelvic collections that resolved with antibiotics; pelvic collections were associated with advanced stage of cancer (P = 0.047).
  • This brought the rectum proximally and anteriorly, aiding with the laparoscopic stapler transection of the distal rectum, especially if the cancer was distal, the patient was obese, and the pelvis was narrow.
  • Further randomized, controlled studies that include assessing five-year cancer survival/recurrence, pelvic nerve dysfunction, and bowel function are needed before laparoscopic ultralow anterior resection becomes widely accepted.
  • [MeSH-major] Adenocarcinoma / surgery. Anal Canal / surgery. Colonic Pouches. Laparoscopy / methods. Proctocolectomy, Restorative / methods. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18679748.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Interactive Tutorial
  • [Publication-country] United States
  •  go-up   go-down


56. Abbas A, Yang G, Fakih M: Management of anal cancer in 2010. Part 1: Overview, screening, and diagnosis. Oncology (Williston Park); 2010 Apr 15;24(4):364-9
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of anal cancer in 2010. Part 1: Overview, screening, and diagnosis.
  • Although anal cancer is a rare disease, its incidence is increasing in men and women worldwide.
  • Anal cancer is generally preceded by high-grade anal intraepithelial neoplasia (HGAIN), which is most prevalent in human immunodeficiency virus (HIV)-positive men who have sex with men.
  • Meta-analysis suggests that 80% of anal cancers could be avoided by vaccination against HPV 16/18.
  • Nearly half of all patients with anal cancer present with rectal bleeding.
  • According to the Surveillance Epidemiology and End Results (SEER) database, 50% of patients with anal cancer have disease localized to the anus, 29% have regional lymph node involvement or direct spread beyond the primary, and 12% have metastatic disease, while 9% have an unknown stage.
  • Clinical staging of anal carcinoma requires a digital rectal exam and a computed tomography scan of the chest, abdomen, and pelvis.
  • The 5-year relative survival rates are 80.1% for localized anal cancer, 60.7% for regional disease, and 29.4% for metastatic disease.
  • Part 2 of this two-part review will address the treatment of anal cancer, highlighting studies of chemoradiation.
  • [MeSH-major] Anus Neoplasms / diagnosis. Anus Neoplasms / prevention & control. Mass Screening

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20464850.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 94
  •  go-up   go-down


57. Winton Ed, Heriot AG, Ng M, Hicks RJ, Hogg A, Milner A, Leong T, Fay M, MacKay J, Drummond E, Ngan SY: The impact of 18-fluorodeoxyglucose positron emission tomography on the staging, management and outcome of anal cancer. Br J Cancer; 2009 Mar 10;100(5):693-700
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of 18-fluorodeoxyglucose positron emission tomography on the staging, management and outcome of anal cancer.
  • Accurate inguinal and pelvic nodal staging in anal cancer is important for the prognosis and planning of radiation fields.
  • There is evidence for the role of 18-fluorodeoxyglucose positron emission tomography (FDG-PET) in the staging and management of cancer, with early reports of an increasing role in outcome prognostication in a number of tumours.
  • We aimed to determine the effect of FDG-PET on the nodal staging, radiotherapy planning and prognostication of patients with primary anal cancer.
  • Sixty-one consecutive patients with anal cancer who were referred to a tertiary centre between August 1997 and November 2005 were staged with conventional imaging (CIm) (including computed tomography (CT), magnetic resonance imaging, endoscopic ultrasound and chest X-ray) and by FDG-PET.
  • The stage determined by CIm and the proposed management plan were prospectively recorded and changes in stage and management as a result of FDG-PET assessed.
  • Kaplan-Meier survival analysis was used to estimate survival for the whole cohort and by FDG-PET and CIm stage.
  • The tumour-stage group was changed in 23% (14 out of 61) as a result of FDG-PET (15% up-staged, 8% down-staged).
  • Fourteen percent of T1 patients (3 out of 22), 42% of T2 patients (10 out of 24) and 40% of T3-4 patients (6 out of 15) assessed using CIm, had a change in their nodal or metastatic stage following FDG-PET.
  • FDG-PET shows increased sensitivity over CIm for staging nodal disease in anal cancer and changes treatment intent or radiotherapy prescription in a significant proportion of patients.
  • [MeSH-major] Anus Neoplasms / diagnosis. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / therapy. Fluorodeoxyglucose F18. Positron-Emission Tomography / methods

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2001 Mar;218(3):776-82 [11230656.001]
  • [Cites] Gynecol Oncol. 1989 May;33(2):168-71 [2703175.001]
  • [Cites] Cancer. 2001 Aug 15;92(4):886-95 [11550162.001]
  • [Cites] Radiology. 1999 Nov;213(2):530-6 [10551237.001]
  • [Cites] N Engl J Med. 2000 Mar 16;342(11):792-800 [10717015.001]
  • [Cites] JAMA. 2001 Feb 21;285(7):914-24 [11180735.001]
  • [Cites] Br J Haematol. 2001 Nov;115(2):272-8 [11703321.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Apr;29(4):506-15 [11914889.001]
  • [Cites] Gynecol Oncol. 2002 Apr;85(1):179-84 [11925141.001]
  • [Cites] Clin Lymphoma. 2003 Jun;4(1):43-9 [12837154.001]
  • [Cites] Semin Surg Oncol. 2003;21(3):149-55 [14508847.001]
  • [Cites] Dis Colon Rectum. 2004 Apr;47(4):451-8 [14978612.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] AJR Am J Roentgenol. 1983 Jan;140(1):95-9 [6600330.001]
  • [Cites] Cancer. 1984 Mar 15;53(6):1285-93 [6692319.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Cancer. 1998 May 1;82(9):1664-71 [9576286.001]
  • [Cites] J Surg Oncol. 1999 Feb;70(2):71-7 [10084647.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1686-93 [10223561.001]
  • [Cites] J Nucl Med. 1999 Aug;40(8):1257-63 [10450675.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):41-5 [10458216.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jun 1;62(2):479-85 [15890590.001]
  • [Cites] Dis Colon Rectum. 2005 Jun;48(6):1301-15 [15793642.001]
  • [Cites] Mol Imaging Biol. 2005 Jul-Aug;7(4):309-13 [16028002.001]
  • [Cites] Eur J Surg Oncol. 2006 Apr;32(3):247-52 [16289647.001]
  • [Cites] Radiother Oncol. 2006 Mar;78(3):254-61 [16545881.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):720-5 [16626889.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2006 Jul;33(7):770-8 [16550384.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Feb 1;70(2):419-24 [17919842.001]
  • [Cites] Pneumologie. 2001 Aug;55(8):367-77 [11505288.001]
  • (PMID = 19259091.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] England
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Other-IDs] NLM/ PMC2653751
  •  go-up   go-down


58. Anand BS, Verstovsek G, Cole G: Tubulovillous adenoma of anal canal: a case report. World J Gastroenterol; 2006 Mar 21;12(11):1780-1
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tubulovillous adenoma of anal canal: a case report.
  • Tumors arising from the anal canal are usually of epithelial origin and are mostly squamous cell carcinoma or basal cell carcinoma.
  • We present a case of benign anal adenomas arising from the anus, an extremely rare diagnosis.
  • Examination revealed a 4 cm friable mass attached to the anus by a stalk.
  • The squamocolumnar junction was visible at the edges of the lesion confirming the anal origin of the tumor.
  • We believe the tubulovillus adenoma arose from either an anal gland or its duct that opens into the anus.
  • Although seen rarely, it is important to recognize and treat these tumors at an early stage because of their potential to transform into adenocarcinoma.
  • [MeSH-major] Adenoma, Villous / diagnosis. Anus Neoplasms / diagnosis
  • [MeSH-minor] Aged. Anal Canal / pathology. Cell Transformation, Neoplastic. Humans. Male

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] J Clin Pathol. 2005 Feb;58(2):217-9 [15677547.001]
  • [Cites] Br J Surg. 1995 Dec;82(12):1634 [8548224.001]
  • (PMID = 16586552.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4124358
  •  go-up   go-down


59. Rogers LJ, Howard B, Van Wijk L, Wei W, Dehaeck K, Soeters R, Denny LA: Chemoradiation in advanced vulval carcinoma. Int J Gynecol Cancer; 2009 May;19(4):745-51
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoradiation in advanced vulval carcinoma.
  • INTRODUCTION: Vulval carcinoma is uncommon, affecting approximately 2 per 100,000 women annually.
  • Advanced vulval carcinomas involve midline structures (such as clitoris, urethra, or anus) and/or adjacent pelvic organs or bone, and adequate excision may require urinary diversion, colostomy, or pelvic exenteration.
  • Less morbid and less mutilating therapeutic alternatives have been investigated, particularly chemoradiation, which has shown success in the management of anal carcinomas.
  • This is a retrospective study of the GSH's experience of the use of chemoradiation as primary therapy for women with advanced vulval carcinoma.
  • Other prognostic factors for survival were performance status and tumor stage.
  • Performance status, age, and tumor stage were also associated with survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Vulvar Neoplasms / drug therapy. Vulvar Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19509582.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


60. Seo Y, Kinsella MT, Reynolds HL, Chipman G, Remick SC, Kinsella TJ: Outcomes of chemoradiotherapy with 5-Fluorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeficient patients. Int J Radiat Oncol Biol Phys; 2009 Sep 1;75(1):143-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of chemoradiotherapy with 5-Fluorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeficient patients.
  • PURPOSE: Information is limited as to how we should treat invasive anal squamous cell carcinoma (SCC) in patients with chronic immunosuppression, since the majority of clinical studies to date have excluded such patients.
  • The objective of this study is to compare treatment outcomes in immunocompetent (IC) versus immunodeficient (ID) patients with invasive anal SCC treated similarly with combined modality therapy.
  • There were no significant differences in tumor size, T stage, N stage, chemotherapy doses, or radiation doses between the two groups.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Radiotherapy, Conformal

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19203845.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


61. Lefevre JH, Parc Y, Kernéis S, Shields C, Touboul E, Chaouat M, Tiret E: Abdomino-perineal resection for anal cancer: impact of a vertical rectus abdominis myocutaneus flap on survival, recurrence, morbidity, and wound healing. Ann Surg; 2009 Nov;250(5):707-11
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abdomino-perineal resection for anal cancer: impact of a vertical rectus abdominis myocutaneus flap on survival, recurrence, morbidity, and wound healing.
  • OBJECTIVES: To evaluate the results of a vertical rectus abdominis myocutaneus (VRAM) flap after abdomino-perineal resection (APR) for anal cancer (AC).
  • The groups (VRAM vs. No VRAM) differed in age at surgery (56.3 vs. 62.1; P = 0.0263); administration of chemotherapy in addition to radiotherapy (81% vs. 59%; P = 0.0218); and stage (ypT3-T4 67.6% vs. 38.4%; P = 0.0394).
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Postoperative Complications. Surgical Flaps. Wound Healing

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19801930.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Chen YW, Yen SH, Chen SY, Huang PI, Shiau CY, Liu YM, Lin JK, Wang LW: Anus-preservation treatment for anal cancer: retrospective analysis at a single institution. J Surg Oncol; 2007 Oct 1;96(5):374-80
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anus-preservation treatment for anal cancer: retrospective analysis at a single institution.
  • BACKGROUND: To evaluate anus-preservation treatment for anal cancer.
  • METHODS: Review of 42 patients (24 M/18 F; median age, 70 years; range, 13-95) with stage I-IIIB disease (squamous cell carcinoma [SqCC], 33; adenocarcinoma, 9) who received curative radiotherapy between 1991 and 2004.
  • Five-year functional anus-preservation rate was 64%.
  • In multivariate analysis, OS was affected by performance status (P < 0.001), N stage (P = 0.009), and pathological type (P = 0.006).
  • Only N stage (P = 0.001) affected DFS.
  • CONCLUSION: With careful monitoring of toxicity, non-surgical anus-preservation treatment with good tumor control is feasible.
  • [MeSH-major] Adenocarcinoma / therapy. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 Wiley-Liss, Inc
  • (PMID = 17492635.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


63. Oblak I, Petric P, Anderluh F, Velenik V, Hudej R, Fras AP: Anal cancer chemoirradiation with curative intent - a single institution experience. Neoplasma; 2009;56(2):150-5
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal cancer chemoirradiation with curative intent - a single institution experience.
  • Results of radiochemotherapy in 50 patients with squamous cell carcinoma of the anal canal, treated with radical radiochemotherapy between January 2003 and September 2007, at the Institute of Oncology Ljubljana are presented.
  • In the multivariate analysis, nodal stage was identified as an independent prognostic factor for LRC, DSS and CFS and application of Mitomycin C for OS.
  • Late anal stenosis, chronic ulceration and grade 2-3 incontinence developed in 3 (6 %), 2 (4 %) and 5 (10 %) of colostomy-free survivors, respectively.
  • </p> KEYWORDS: anal cancer, radiochemotherapy, survival, toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19239330.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


64. Oehler-Jänne C, Huguet F, Provencher S, Seifert B, Negretti L, Riener MO, Bonet M, Allal AS, Ciernik IF: HIV-specific differences in outcome of squamous cell carcinoma of the anal canal: a multicentric cohort study of HIV-positive patients receiving highly active antiretroviral therapy. J Clin Oncol; 2008 May 20;26(15):2550-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-specific differences in outcome of squamous cell carcinoma of the anal canal: a multicentric cohort study of HIV-positive patients receiving highly active antiretroviral therapy.
  • PURPOSE: To define clinical outcome after definitive chemoradiotherapy (CRT) of anal carcinoma in HIV-infected patients treated with highly active antiretroviral therapy (HAART).
  • Local disease control (LC), relapse-free survival (RFS), overall survival (OS), cancer-specific survival (CSS), toxicity, and prognostic factors were investigated.
  • RESULTS: HIV-positive patients were younger (mean age, 48 v 62 years; P < .0005), predominantly male (93% v 25%; P < .0005), and with early-stage (P = .06) and large-cell histology (90% v 67%; P = .005) disease.
  • CONCLUSION: Long-term LC and acute toxicity represent major clinical challenges in HIV-positive patients with anal carcinoma.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy. HIV Infections / drug therapy


65. Alvarez G, Perry A, Tan BR, Wang HL: Expression of epidermal growth factor receptor in squamous cell carcinomas of the anal canal is independent of gene amplification. Mod Pathol; 2006 Jul;19(7):942-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of epidermal growth factor receptor in squamous cell carcinomas of the anal canal is independent of gene amplification.
  • The EGFR status in squamous cell carcinoma of the anal canal, an uncommon malignancy traditionally treated with chemoradiation, has not been well investigated.
  • In this study, 38 primary squamous cell carcinomas of the anal canal were immunohistochemically examined for EGFR expression and analyzed by fluorescence in situ hybridization (FISH) for EGFR gene copy numbers.
  • There were no significant differences among tumors stratified by stage, degree of keratinization, or tissue block storage times.
  • These results demonstrate that EGFR is overexpressed in more than one-half of the squamous cell carcinomas of the anal canal through mechanisms other than gene amplification.
  • [MeSH-major] Anus Neoplasms / metabolism. Carcinoma, Squamous Cell / metabolism. Receptor, Epidermal Growth Factor / metabolism. Up-Regulation

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16648870.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


66. Pucciarelli S, Capirci C, Emanuele U, Toppan P, Friso ML, Pennelli GM, Crepaldi G, Pasetto L, Nitti D, Lise M: Relationship between pathologic T-stage and nodal metastasis after preoperative chemoradiotherapy for locally advanced rectal cancer. Ann Surg Oncol; 2005 Feb;12(2):111-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between pathologic T-stage and nodal metastasis after preoperative chemoradiotherapy for locally advanced rectal cancer.
  • BACKGROUND: We investigated the relationship between pathologic T-stage and mesorectal metastases after preoperative chemoradiotherapy (CRT) for clinical stage II to III rectal carcinoma.
  • METHODS: The records of consecutive patients with clinical stage II to III carcinoma of the mid or low rectum who underwent surgery after CRT were reviewed.
  • Indications for preoperative CRT were cancer up to 11 cm from the anal verge, Eastern Cooperative Oncology Group performance status of 0 to 2, age 18 to 75 years, and clinical tumor-node-metastasis stage II or III.
  • The pretreatment tumor-node-metastasis stage was as follows: I, n = 1; II, n = 96; and III, n = 138.
  • According to the pT stage, the rate of node positivity was 2% for pT0, 15% for pT1, 17% for pT2, 38% for pT3, and 33% for pT4 cases.
  • On considering pT stage alone, the odds ratio was in the region of 10 for pT1/2 and >20 for pT3/4 patients.
  • CONCLUSIONS: In patients with pT0 after preoperative CRT for clinical stage II to III mid or low rectal cancer, the risk of nodal metastases is very low.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2005 Feb;12(2):95-7 [15827785.001]
  • (PMID = 15827790.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


67. Piperkova E, Raphael B, Altinyay M, Castellon I, Libes R, Sandella N, Abdel-Dayem H: Impact of PET/CT on initial staging, restaging and treatment management of anal cancer: a clinical case with literature review. J BUON; 2006 Oct-Dec;11(4):523-7
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of PET/CT on initial staging, restaging and treatment management of anal cancer: a clinical case with literature review.
  • Distant extrapelvic metastases appear in approximately in 10% of the patients with squamous cell anal cancer (SCAC) and survival depends on the treatment strategy.
  • We present a patient with SCAC in whom, according to PET/CT findings, the initial stage was changed from II (T2N0M0) to III A (T2N2M0).
  • Radiation therapy (RT) and chemotherapy achieved a good therapeutic response but early follow up revealed new paraaortic lymph node (LN) metastases, as well as an uncommon left supraclavicular LN metastasis from the same primary carcinoma.
  • The disease was restaged as stage IV (T2N2M1) and radiation therapy was substituted by chemotherapy.
  • [MeSH-major] Anus Neoplasms / radiography. Anus Neoplasms / radionuclide imaging. Carcinoma, Squamous Cell / radiography. Carcinoma, Squamous Cell / radionuclide imaging. Fluorodeoxyglucose F18. Positron-Emission Tomography. Radiopharmaceuticals. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17309188.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


68. Morikawa A, Williams TY, Dirix L, Colpaert C, Goodman M, Lyles RH, Zhong D, Zhou W: Allelic imbalances of chromosomes 8p and 18q and their roles in distant relapse of early stage, node-negative breast cancer. Breast Cancer Res; 2005;7(6):R1051-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allelic imbalances of chromosomes 8p and 18q and their roles in distant relapse of early stage, node-negative breast cancer.
  • INTRODUCTION: Identification of breast cancer patients at risk for postoperative distant relapse is an important clinical issue.
  • METHODS: Using 'counting alleles', a novel experimental method, we determined allelic status of chromosomes 8p and 18q in a case-control study with 65 early stage, node negative, invasive ductal carcinomas (IDCs).
  • CONCLUSION: Our finding suggests that differential allelic loss of chromosomes 8p and 18q may represent subtypes of early stage IDC with different tumor progression behaviors.
  • [MeSH-major] Allelic Imbalance. Breast Neoplasms / genetics. Carcinoma, Ductal, Breast / genetics. Chromosomes, Human, Pair 18 / genetics. Chromosomes, Human, Pair 8 / genetics

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2002 Jan 31;415(6871):484-5 [11831227.001]
  • [Cites] Lancet. 2002 Jan 19;359(9302):219-25 [11812558.001]
  • [Cites] Clin Cancer Res. 2002 Dec;8(12):3863-9 [12473601.001]
  • [Cites] Curr Opin Oncol. 2003 Jan;15(1):50-4 [12490761.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Prostate. 2004 Sep 15;61(1):81-91 [15287096.001]
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2527-30 [8653691.001]
  • [Cites] J Mol Med (Berl). 1997 Jun;75(6):429-39 [9231883.001]
  • [Cites] Nat Biotechnol. 1998 Jan;16(1):49-53 [9447593.001]
  • [Cites] Anticancer Res. 1998 Mar-Apr;18(2A):1031-6 [9615760.001]
  • [Cites] Nat Biotechnol. 1996 Mar;14(3):303-8 [9630890.001]
  • [Cites] Genet Anal. 1999 Feb;14(5-6):151-6 [10084107.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9236-41 [10430926.001]
  • [Cites] Breast Cancer Res. 2004;6(6):229-39 [15535852.001]
  • [Cites] Cancer Res. 2000 Feb 15;60(4):854-7 [10706093.001]
  • [Cites] Int J Cancer. 2000 May 20;89(3):305-10 [10861509.001]
  • [Cites] Nat Biotechnol. 2001 Jan;19(1):78-81 [11135558.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):818-22 [11221861.001]
  • [Cites] J Pathol. 2001 Apr;193(4):442-9 [11276002.001]
  • [Cites] Curr Opin Oncol. 2002 Jan;14(1):65-72 [11790983.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13647-52 [12370419.001]
  • (PMID = 16457686.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1410773
  •  go-up   go-down


69. Chiao EY, Krown SE, Stier EA, Schrag D: A population-based analysis of temporal trends in the incidence of squamous anal canal cancer in relation to the HIV epidemic. J Acquir Immune Defic Syndr; 2005 Dec 1;40(4):451-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A population-based analysis of temporal trends in the incidence of squamous anal canal cancer in relation to the HIV epidemic.
  • Squamous cell carcinoma of the anal canal (SCCA) is etiologically linked to human papillomavirus, and its incidence is increased among the immunosuppressed.
  • The gap in SCCA incidence between women and men decreased from a ratio of 1.6:1 in the pre-HIV era to 1.5:1 in the HIV era and to 1.2:1 in the HAART era.
  • Men were more likely to be diagnosed with early-stage disease, but they were less likely than women to receive radiation therapy.
  • [MeSH-major] Anus Neoplasms / epidemiology. Carcinoma, Squamous Cell / epidemiology. HIV Infections / epidemiology


70. Pasetto LM, Friso ML, Pucciarelli S, Basso U, Toppan P, Rugge M, Sinigaglia G, Nitti D, Sotti G, Monfardini S: Primary rectal carcinoma in patients with stage IV resectable disease at diagnosis. Anticancer Res; 2007 Mar-Apr;27(2):1079-85
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary rectal carcinoma in patients with stage IV resectable disease at diagnosis.
  • BACKGROUND: Rectal cancer is commonly diagnosed at a precocious stage, but for patients presenting at diagnosis with stage IV disease the best treatment is still undefined.
  • The purpose of this study was to review the feasibility and outcome of multimodality treatment of rectal cancer patients metastatic at diagnosis.
  • PATIENTS AND METHODS: From January 2000 to December 2005, 40 patients with histologically proven stage IV rectal adenocarcinoma (< 12 cm from the anal verge) were examined.
  • CONCLUSION: The best treatment on diagnosis of metastatic rectal cancer is a multimodality CHT-RT approach.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17465247.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 7673326042 / irinotecan; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


71. Buttarelli M, Houvenaeghel G, Lelièvre L, Jacquemier J, Guiramand J, Delpero JR: [Pelvic posterior exenteration with immediate colo-rectal anastomosis: is it justified and feasible in advanced stage ovarian carcinoma?]. Ann Chir; 2006 Oct;131(8):431-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pelvic posterior exenteration with immediate colo-rectal anastomosis: is it justified and feasible in advanced stage ovarian carcinoma?].
  • [Transliterated title] Une exentération pelvienne postérieure avec anastomose est-elle faisable et justifiée dans le traitement des cancers de l'ovaire à un stade évolué?
  • PURPOSE: The aim of this study is to show that the removal of the rectum is not an obstacle to implement an optimal surgery in advanced epithelial cancer of the ovary.
  • MATERIAL AND METHODS: Retrospective study on a population of 44 women with advanced epithelial cancer of the ovary.
  • All the assessable patients (43/44) have an anal satisfactory continence.
  • CONCLUSION: The posterior exenteration, when it's necessary, for advanced epithelial cancer of the ovary must not be an obstacle to obtain an optimal surgery.
  • Anal continence is respected and there are no more complications.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Endometrioid / surgery. Carcinosarcoma / surgery. Colon / surgery. Ovarian Neoplasms / surgery. Pelvic Exenteration. Rectum / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16707093.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


72. Abbas A, Yang G, Fakih M: Management of anal cancer in 2010. Part 2: current treatment standards and future directions. Oncology (Williston Park); 2010 Apr 30;24(5):417-24
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of anal cancer in 2010. Part 2: current treatment standards and future directions.
  • The treatment of anal squamous cell cancer with definitive chemoradiation is the gold-standard therapy for localized anal cancer, primarily because of its sphincter-saving and colostomy-sparing potential.
  • In the concluding part of this review, we consider the data on chemoradiation with 5-FU/mitomycin vs radiation alone, chemoradiation with 5-FU/mitomycin vs chemoradiation with 5-FU alone, neoadjuvant chemotherapy with cisplatin/5-FU followed by cisplatin/5-FU plus radiation vs mitomycin/5-FU plus radiation, the addition of induction or maintenance chemotherapy to chemoradiation, the effect of overall treatment time on tumor control, whether chemotherapy can be eliminated for early-stage anal cancer, and the impact of human immunodeficiency virus infection on treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Oncology (Williston Park). 2010 Apr 30;24(5):427-30 [20480742.001]
  • [CommentIn] Oncology (Williston Park). 2010 Apr 30;24(5):424-7 [20480741.001]
  • (PMID = 20480740.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Number-of-references] 52
  •  go-up   go-down


73. Myerson RJ, Outlaw ED, Chang A, Birnbaum EH, Fleshman JW, Grigsby PW, Kodner IJ, Malayapa RS, Mutch MG, Parikh P, Picus J, Tan BR: Radiotherapy for epidermoid carcinoma of the anus: thirty years' experience. Int J Radiat Oncol Biol Phys; 2009 Oct 1;75(2):428-35
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy for epidermoid carcinoma of the anus: thirty years' experience.
  • PURPOSE: To evaluate the factors associated with disease control and morbidity after radiotherapy for anal carcinoma.
  • METHODS AND MATERIALS: Between 1975 and 2005, 194 patients with localized epidermoid anal carcinoma underwent radiotherapy.
  • Univariate analysis for UNED survival showed a strong association with the T and N stage (5-year UNED rate, 88.5% +/- 3.4% for those with Stage T1-T2N0; 70.1% +/- 4.2% for Stage T3N0; and 52.7% +/- 6.6% for Stage III; p > .001) and mobility on palpation (5-year UNED rate, 89.2% +/- 4.6% for those with mobile tumors vs. 59.3% +/- 6.1% for those with tethered/fixed tumor; p > .001).
  • Of the 194 patients, 56 had 68 additional malignancies, mainly either antedating the anal cancer or outside the radiation fields.
  • [MeSH-major] Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy

  • Genetic Alliance. consumer health - Epidermoid Carcinoma.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19251377.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


74. Stewart D, Yan Y, Kodner IJ, Birnbaum E, Fleshman J, Myerson R, Dietz D: Salvage surgery after failed chemoradiation for anal canal cancer: should the paradigm be changed for high-risk tumors? J Gastrointest Surg; 2007 Dec;11(12):1744-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage surgery after failed chemoradiation for anal canal cancer: should the paradigm be changed for high-risk tumors?
  • It is common belief that patients failing chemoradiation therapy (CRT) for squamous cell cancer of the anus (SCCA) can be salvaged with subsequent surgery.
  • Initial tumors were AJCC stage 2 (16 cases), 3A (3 cases), and 4 (1 case).
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Salvage Therapy


75. Sharma P, Kumar N, Bahadur AK, Shukla DK: Quantitative analysis of radiation-associated cellular changes in oral cancer and their correlations with histologic grade and clinical stage: a multivariate evaluation of 43 patients. Anal Quant Cytol Histol; 2005 Apr;27(2):111-7
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative analysis of radiation-associated cellular changes in oral cancer and their correlations with histologic grade and clinical stage: a multivariate evaluation of 43 patients.
  • OBJECTIVE: To quantitate radiation-associated cytologic abnormalities in oral cancer cells and analyze their relationships with radiation dose, clinical stage and histologic grade.
  • STUDY DESIGN: Forty-three oral cancer patients receiving 2 Gy of fractionated radiotherapy per day were enrolled.
  • The variation in these counts with increasing radiation dose was assessed and compared with the histologic grade and clinical stage.
  • Most cytologic features were not significantly different in early and advanced clinical stage cancers before or after irradiation (Mann-Whitney U test).
  • CONCLUSION: Cellular changes do not show a relationship with clinical stage either before or after irradiation.
  • Since micronucleation and nuclear budding remain significantly different between histologic grades even after 24 Gy of irradiation, they may be utilized as clinically practicable alternatives to biopsy at this stage and may be useful in further studies on cytologic prognostication of irradiated oral cancer.

  • Genetic Alliance. consumer health - Oral cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15913204.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Winter L, Bruhn H, Langrehr J, Neuhaus P, Felix R, Hänninen LE: Magnetic resonance imaging in suspected rectal cancer: determining tumor localization, stage, and sphincter-saving resectability at 3-Tesla-sustained high resolution. Acta Radiol; 2007 May;48(4):379-87
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging in suspected rectal cancer: determining tumor localization, stage, and sphincter-saving resectability at 3-Tesla-sustained high resolution.
  • PURPOSE: To assess image quality and overall accuracy of 3-Tesla (3T)-sustained high-resolution magnetic resonance (MR) imaging for diagnostic preoperative workup in suspected rectal carcinoma.
  • MATERIAL AND METHODS: Twenty-three patients with suspected rectal cancer underwent unenhanced and contrast-enhanced fat-suppressed pelvic high-resolution MR imaging using a four-channel phased-array pelvic coil at 3T.
  • Image quality, tumor stage, distance from the anorectal margin, and sphincter-saving resectability were prospectively assessed by two blinded readers.
  • T stage and N stage were correctly diagnosed in 95% and 91%, respectively.
  • CONCLUSION: MR imaging with phased-array receiver coils at 3T facilitated both visualization of different pathologic conditions of the rectum and accurate determination of tumor stage in rectal carcinomas.
  • Thus, this noninvasive diagnostic approach appeared highly suitable for the assessment of patients with suspected rectal carcinoma.
  • [MeSH-major] Anal Canal / surgery. Image Processing, Computer-Assisted / methods. Magnetic Resonance Imaging / methods. Rectal Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17453515.001).
  • [ISSN] 0284-1851
  • [Journal-full-title] Acta radiologica (Stockholm, Sweden : 1987)
  • [ISO-abbreviation] Acta Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


77. Steinbakk A, Malpica A, Slewa A, Gudlaugsson E, Janssen EA, Arends M, Kruse AJ, Yinhua Y, Feng W, Baak JP: High frequency microsatellite instability has a prognostic value in endometrial endometrioid adenocarcinoma, but only in FIGO stage 1 cases. Anal Cell Pathol (Amst); 2010;33(5):245-55

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High frequency microsatellite instability has a prognostic value in endometrial endometrioid adenocarcinoma, but only in FIGO stage 1 cases.
  • OBJECTIVES: to analyze the prognostic value of microsatellite instability (MSI) in a population-based study of FIGO stage 1-4 endometrial endometrioid adenocarcinomas.
  • [MeSH-major] Biomarkers, Tumor / genetics. Carcinoma, Endometrioid / genetics. Microsatellite Instability

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ReprintIn] Cell Oncol (Dordr). 2011 Oct;34(5):457-65 [21547578.001]
  • (PMID = 21079294.001).
  • [ISSN] 2210-7185
  • [Journal-full-title] Analytical cellular pathology (Amsterdam)
  • [ISO-abbreviation] Anal Cell Pathol (Amst)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC4605578
  •  go-up   go-down


78. Liang S, Singh M, Gam LH: The differential expression of aqueous soluble proteins in breast normal and cancerous tissues in relation to stage and grade of patients. J Biomed Biotechnol; 2010;2010:516469
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The differential expression of aqueous soluble proteins in breast normal and cancerous tissues in relation to stage and grade of patients.
  • Breast cancer is a leading cause of female deaths worldwide.
  • In Malaysia, it is the most common form of female cancer while Infiltrating ductal carcinoma (IDC) is the most common form of breast cancer.
  • The patients were divided into different cohorts according to tumour stage and grade.
  • In this study, we found that by defining the expression of the proteins according to stages and grades of IDC, a significant relationship between the expression of the proteins with the stage or grade of IDC can be established, which increases the usefulness of these proteins as biomarkers for IDC.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] J Biol Chem. 1975 May 25;250(10):4007-21 [236308.001]
  • [Cites] Anticancer Res. 1990 Mar-Apr;10(2A):343-51 [2346307.001]
  • [Cites] Anal Biochem. 1993 Jul;212(1):206-11 [8368495.001]
  • [Cites] Mol Cell Biochem. 1994 Jun 15;135(1):71-8 [7816058.001]
  • [Cites] Electrophoresis. 1995 Jul;16(7):1215-24 [7498169.001]
  • [Cites] Biochem Biophys Res Commun. 1996 May 15;222(2):619-25 [8670254.001]
  • [Cites] J Endocrinol. 1996 Sep;150 Suppl:S65-71 [8943789.001]
  • [Cites] Mol Cell Biol. 1997 Jan;17(1):256-66 [8972206.001]
  • [Cites] Electrophoresis. 1997 Mar-Apr;18(3-4):582-7 [9150945.001]
  • [Cites] Electrophoresis. 1997 Mar-Apr;18(3-4):588-98 [9150946.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12589-94 [10535966.001]
  • [Cites] Mol Carcinog. 2000 Mar;27(3):158-65 [10708477.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2000;40:617-47 [10836149.001]
  • [Cites] Cancer Res. 2001 Jan 1;61(1):76-80 [11196201.001]
  • [Cites] Lancet. 2002 Feb 16;359(9306):572-7 [11867112.001]
  • [Cites] FEBS Lett. 2002 Feb 20;513(1):53-7 [11911880.001]
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):931-43 [14737123.001]
  • [Cites] Proteomics. 2004 Mar;4(3):793-811 [14997500.001]
  • [Cites] Breast Cancer Res. 2004;6(3):109-18 [15084231.001]
  • [Cites] J Proteome Res. 2004 May-Jun;3(3):604-12 [15253443.001]
  • [Cites] Breast. 2004 Oct;13(5):389-96 [15454194.001]
  • [Cites] Electrophoresis. 1997 Dec;18(15):2832-41 [9504817.001]
  • [Cites] Electrophoresis. 1998 Feb;19(2):333-43 [9548300.001]
  • [Cites] Mol Neurobiol. 1998 Jun;16(3):269-84 [9626666.001]
  • [Cites] Biotechnology (N Y). 1996 Jan;14(1):61-5 [9636313.001]
  • [Cites] Nature. 1998 Jul 2;394(6688):88-92 [9665134.001]
  • [Cites] Trends Biochem Sci. 1998 Oct;23(10):399-402 [9810229.001]
  • [Cites] Methods Mol Biol. 1999;112:95-7 [10027232.001]
  • [Cites] Electrophoresis. 1999 Jul;20(10):2100-10 [10451122.001]
  • [Cites] Mol Cell Proteomics. 2005 Apr;4(4):523-33 [15684406.001]
  • [Cites] Proteomics. 2005 Jul;5(10):2602-11 [15924290.001]
  • [Cites] Proteomics. 2006 Jun;6(11):3352-68 [16637015.001]
  • [Cites] Cancer Invest. 2007 Sep;25(6):378-83 [17882647.001]
  • [Cites] Clin Chim Acta. 2008 Feb;388(1-2):106-14 [17996735.001]
  • [Cites] Biotechnol Appl Biochem. 2009 Mar;52(Pt 3):209-19 [18564057.001]
  • [Cites] Dis Markers. 2010;28(3):149-65 [20534901.001]
  • [Cites] J Cell Mol Med. 2010 Dec;14(12):2780-9 [19840198.001]
  • (PMID = 21197096.001).
  • [ISSN] 1110-7251
  • [Journal-full-title] Journal of biomedicine & biotechnology
  • [ISO-abbreviation] J. Biomed. Biotechnol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC3004415
  •  go-up   go-down


79. Sinha S, Sinha N, Bandyopadhyay R, Mondal SK: Robinson's cytological grading on aspirates of breast carcinoma: Correlation with Bloom Richardson's histological grading. J Cytol; 2009 Oct;26(4):140-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Robinson's cytological grading on aspirates of breast carcinoma: Correlation with Bloom Richardson's histological grading.
  • BACKGROUND: Cytological grading (CG) on aspirates of breast carcinoma is a useful tool for surgical maneuver and prognosis.
  • AIMS: An endeavor was made to use CG on aspirates of breast carcinoma using Robinson's grade and to correlate it with Bloom Richardsons' histopathological grading.
  • MATERIALS AND METHODS: A total of 59 patients of breast carcinoma, aged 28-57 years, were aspirated and the smears were graded using Robinson's criteria.
  • All grade I had stage A, two of grade II had stage B, while all grade III had either stage B or stage C disease.
  • CONCLUSIONS: Thus, CG of breast carcinoma correlates well with histopathological grading and may well be useful as a prognostic marker.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 1991 Nov;19(5):403-10 [1757079.001]
  • [Cites] Anal Quant Cytol Histol. 1987 Dec;9(6):480-4 [2829937.001]
  • [Cites] Lancet. 1994 Apr 16;343(8903):947-9 [7909010.001]
  • [Cites] Diagn Cytopathol. 1997 Apr;16(4):295-311 [9143822.001]
  • [Cites] Cancer. 1997 Feb 25;81(1):16-21 [9100536.001]
  • [Cites] Diagn Cytopathol. 1995 Oct;13(3):260-5 [8575287.001]
  • [Cites] Diagn Cytopathol. 1995 Dec;13(5):388-95 [8834313.001]
  • [Cites] Diagn Cytopathol. 1996 Aug;15(2):116-20 [8872432.001]
  • [Cites] Diagn Cytopathol. 1994;10(3):203-8 [8050325.001]
  • (PMID = 21938177.001).
  • [ISSN] 0974-5165
  • [Journal-full-title] Journal of cytology
  • [ISO-abbreviation] J Cytol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3167998
  • [Keywords] NOTNLM ; Bloom Richardson's grading / Breast carcinoma / Robinson's grading / fine needle aspiration cytology
  •  go-up   go-down


80. Ascani G, Balercia P, Messi M, Lupi L, Goteri G, Filosa A, Stramazzotti D, Pieramici T, Rubini C: Angiogenesis in oral squamous cell carcinoma. Acta Otorhinolaryngol Ital; 2005 Feb;25(1):13-7
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiogenesis in oral squamous cell carcinoma.
  • Based on these results, microvessel density was evaluated, in the present study, in 64 cases of squamous cell carcinoma of the oral cavity, using immunohistochemical analysis with anti-CD34 monoclonal antibody.
  • Possible correlations between microvessel density and clinico-pathological parameters were analysed, such as: age, sex, tumour localization and size, TNM stage and histological grading.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Mouth Neoplasms / pathology. Neovascularization, Pathologic / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Oral squamous cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 2000 Apr;6(4):389-95 [10742145.001]
  • [Cites] J Pathol. 1998 Feb;184(2):119-22 [9602700.001]
  • [Cites] Anal Cell Pathol. 2001;22(4):183-92 [11564894.001]
  • [Cites] J Exp Clin Cancer Res. 2001 Dec;20(4):463-8 [11876537.001]
  • [Cites] Head Neck. 2002 Jul;24(7):643-50 [12112537.001]
  • [Cites] Int J Oral Maxillofac Surg. 2004 Jan;33(1):2-7 [14690652.001]
  • [Cites] Sci Am. 1976 May;234(5):58-64, 70-3 [1273568.001]
  • [Cites] Am J Pathol. 1988 Nov;133(2):419-23 [3189515.001]
  • [Cites] J Natl Cancer Inst. 1990 Jan 3;82(1):4-6 [1688381.001]
  • [Cites] N Engl J Med. 1991 Jan 3;324(1):1-8 [1701519.001]
  • [Cites] Lancet. 1992 Jul 18;340(8812):145-6 [1378165.001]
  • [Cites] Eur J Cancer. 1993;29A(8):1141-5 [8390846.001]
  • [Cites] Am J Pathol. 1993 Aug;143(2):401-9 [7688183.001]
  • [Cites] Cancer. 1994 Feb 1;73(3):678-87 [7507798.001]
  • [Cites] J Clin Oncol. 1994 Mar;12(3):454-66 [7509851.001]
  • [Cites] Otolaryngol Head Neck Surg. 1994 Oct;111(4):417-22 [7524005.001]
  • [Cites] Am J Surg. 1994 Nov;168(5):373-80 [7526718.001]
  • [Cites] J Natl Cancer Inst. 1995 Jul 5;87(13):997-1008 [7543156.001]
  • [Cites] Anticancer Res. 1995 Jul-Aug;15(4):1417-22 [7544566.001]
  • [Cites] Br J Oral Maxillofac Surg. 1996 Feb;34(1):37-41 [8645680.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1996 Aug;122(8):865-8 [8703391.001]
  • [Cites] Head Neck. 1996 Jul-Aug;18(4):343-6 [8780945.001]
  • [Cites] Head Neck. 1997 Jul;19(4):276-80 [9213105.001]
  • [Cites] J Pathol. 1997 Sep;183(1):39-43 [9370945.001]
  • [Cites] Oral Oncol. 1997 Sep;33(5):369-74 [9415339.001]
  • [Cites] Lab Invest. 1997 Dec;77(6):659-64 [9426404.001]
  • [Cites] Annu Rev Med. 1998;49:407-24 [9509272.001]
  • [Cites] Clin Cancer Res. 2000 Jul;6(7):2821-8 [10914730.001]
  • (PMID = 16080310.001).
  • [ISSN] 0392-100X
  • [Journal-full-title] Acta otorhinolaryngologica Italica : organo ufficiale della Società italiana di otorinolaringologia e chirurgia cervico-facciale
  • [ISO-abbreviation] Acta Otorhinolaryngol Ital
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD31
  • [Other-IDs] NLM/ PMC2639850
  •  go-up   go-down


81. Hohenberger W, Merkel S, Matzel K, Bittorf B, Papadopoulos T, Göhl J: The influence of abdomino-peranal (intersphincteric) resection of lower third rectal carcinoma on the rates of sphincter preservation and locoregional recurrence. Colorectal Dis; 2006 Jan;8(1):23-33

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The influence of abdomino-peranal (intersphincteric) resection of lower third rectal carcinoma on the rates of sphincter preservation and locoregional recurrence.
  • PATIENTS AND METHODS: The data of 476 patients with a carcinoma in the lower third of the rectum who underwent primary treatment for stage I-III disease by low anterior resection, abdomino-peranal (intersphincteric) resection or abdominoperineal excision between 1985 and 2001 were analysed.
  • The cancer-related 5-year survival rate was not altered by intersphincteric resection.
  • [MeSH-major] Anal Canal / surgery. Carcinoma / surgery. Colectomy / methods. Neoplasm Recurrence, Local / epidemiology. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16519634.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


82. Asahi T, Kondo H, Masuda M, Nishino H, Aratani Y, Naito Y, Yoshikawa T, Hisaka S, Kato Y, Osawa T: Chemical and immunochemical detection of 8-halogenated deoxyguanosines at early stage inflammation. J Biol Chem; 2010 Mar 19;285(12):9282-91
Hazardous Substances Data Bank. L-TYROSINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemical and immunochemical detection of 8-halogenated deoxyguanosines at early stage inflammation.
  • Interestingly, positive mAb8B3 antibody staining was observed in liver tissue from hepatocellular carcinoma patients but not in liver tissue from human cirrhosis patients.

  • Immune Epitope Database and Analysis Resource. gene/protein/disease-specific - Related Immune Epitope Information .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1631-6 [11172002.001]
  • [Cites] J Clin Invest. 1996 Sep 15;98(6):1283-9 [8823292.001]
  • [Cites] Lab Invest. 1997 Mar;76(3):365-74 [9121119.001]
  • [Cites] J Clin Invest. 1997 May 1;99(9):2075-81 [9151778.001]
  • [Cites] J Lipid Res. 1997 Jul;38(7):1334-46 [9254060.001]
  • [Cites] Nature. 1998 Jan 22;391(6665):393-7 [9450756.001]
  • [Cites] Carcinogenesis. 1998 Oct;19(10):1809-14 [9806163.001]
  • [Cites] Diabetes. 1999 Jan;48(1):1-9 [9892215.001]
  • [Cites] Biochemistry. 1998 Dec 22;37(51):17923-30 [9922160.001]
  • [Cites] Infect Immun. 1999 Apr;67(4):1828-36 [10085024.001]
  • [Cites] J Biol Chem. 1999 Jul 16;274(29):20406-14 [10400665.001]
  • [Cites] J Biol Chem. 2004 Dec 3;279(49):51241-9 [15364942.001]
  • [Cites] Free Radic Biol Med. 2005 Jan 1;38(1):24-31 [15589368.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Nov 15;827(1):26-31 [16260376.001]
  • [Cites] J Biol Chem. 2006 Feb 10;281(6):3096-104 [16326702.001]
  • [Cites] Basic Clin Pharmacol Toxicol. 2006 May;98(5):496-502 [16635109.001]
  • [Cites] Free Radic Biol Med. 2006 Aug 15;41(4):620-6 [16863995.001]
  • [Cites] J Biol Chem. 1999 Nov 19;274(47):33440-8 [10559226.001]
  • [Cites] Nature. 2000 Feb 24;403(6772):859-66 [10706276.001]
  • [Cites] Biochemistry. 2001 Feb 20;40(7):2041-51 [11329271.001]
  • [Cites] Biochemistry. 2001 Feb 20;40(7):2052-9 [11329272.001]
  • [Cites] Nucleosides Nucleotides Nucleic Acids. 2001 Mar;20(3):251-60 [11393401.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Oct 9;98(21):11961-6 [11593004.001]
  • [Cites] J Biol Chem. 2001 Nov 2;276(44):40486-96 [11533049.001]
  • [Cites] Free Radic Biol Med. 2001 Dec 1;31(11):1341-51 [11728805.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2081-8 [11733358.001]
  • [Cites] FEBS Lett. 2002 Apr 10;516(1-3):67-70 [11959105.001]
  • [Cites] Toxicology. 2002 Aug 1;177(1):11-22 [12126792.001]
  • [Cites] J Biol Chem. 2002 Nov 29;277(48):46116-22 [12359714.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jan 21;100(2):685-90 [12522148.001]
  • [Cites] J Biol Chem. 2003 Mar 14;278(11):8942-50 [12643282.001]
  • [Cites] Anal Biochem. 2003 Jun 15;317(2):201-9 [12758258.001]
  • [Cites] J Biol Chem. 2003 Jun 27;278(26):23522-8 [12707270.001]
  • [Cites] J Biol Chem. 2003 Sep 19;278(38):36365-72 [12869568.001]
  • [Cites] J Virol. 2004 Aug;78(16):8709-19 [15280479.001]
  • [Cites] Blood. 1990 Aug 15;76(4):655-63 [2200535.001]
  • [Cites] J Biol Chem. 1991 May 15;266(14):9050-4 [1851162.001]
  • [Cites] J Biol Chem. 1993 Feb 25;268(6):4069-77 [8382689.001]
  • [Cites] Gastroenterol Jpn. 1993 Aug;28(4):541-6 [8397132.001]
  • [Cites] Mutat Res. 1994 Mar 1;305(2):253-64 [7510036.001]
  • [Cites] Biol Chem Hoppe Seyler. 1994 Feb;375(2):81-8 [8192861.001]
  • [Cites] J Biol Chem. 1995 Jul 14;270(28):16542-8 [7622459.001]
  • [Cites] Biochem J. 1996 Jan 1;313 ( Pt 1):17-29 [8546679.001]
  • [Cites] Neuro Oncol. 2001 Apr;3(2):73-81 [11296483.001]
  • (PMID = 20081197.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Halogens; 0 / Lipopolysaccharides; 3604-79-3 / 3-nitrotyrosine; 42HK56048U / Tyrosine; 88847-89-6 / 8-oxo-7-hydrodeoxyguanosine; EC 1.11.1.7 / Peroxidase; G9481N71RO / Deoxyguanosine
  • [Other-IDs] NLM/ PMC2838346
  •  go-up   go-down


83. Lorentzen A, Vogel LK, Lewinsky RH, Saebø M, Skjelbred CF, Godiksen S, Hoff G, Tveit KM, Lothe IM, Ikdahl T, Kure EH, Mitchelmore C: Expression of NDRG2 is down-regulated in high-risk adenomas and colorectal carcinoma. BMC Cancer; 2007 Oct 12;7:192
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of NDRG2 is down-regulated in high-risk adenomas and colorectal carcinoma.
  • BACKGROUND: It has recently been shown that NDRG2 mRNA is down-regulated or undetectable in several human cancers and cancer cell-lines.
  • The aim of this study has been to examine NDRG2 mRNA expression in colon cancer.
  • When comparing adenomas/carcinomas with adjacent normal tissue from the same individual, NDRG2 expression levels were significantly reduced in both high-risk adenoma (p < 0.001) and in colorectal carcinoma (p < 0.001).
  • There was a trend for NDRG2 levels to decrease with increasing Dukes' stage (p < 0.05).
  • CONCLUSION: Our results demonstrate that expression of NDRG2 is down-regulated at a late stage during colorectal carcinogenesis.
  • Future studies are needed to address whether NDRG2 down-regulation is a cause or consequence of the progression of colorectal adenomas to carcinoma.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1999 May 13;18(19):3004-16 [10378696.001]
  • [Cites] J Mol Diagn. 2006 May;8(2):193-201 [16645205.001]
  • [Cites] Anal Biochem. 2000 Feb 15;278(2):175-84 [10660460.001]
  • [Cites] Proteins. 2002 May 1;47(2):163-8 [11933063.001]
  • [Cites] Mol Cell Biochem. 2002 Jan;229(1-2):35-44 [11936845.001]
  • [Cites] Scand J Gastroenterol. 2003 Jun;38(6):635-42 [12825872.001]
  • [Cites] Int J Cancer. 2003 Sep 1;106(3):342-7 [12845671.001]
  • [Cites] FEBS Lett. 2003 Oct 23;553(3):413-8 [14572661.001]
  • [Cites] Neurobiol Dis. 2004 Jun;16(1):48-58 [15207261.001]
  • [Cites] Mech Dev. 1999 May;83(1-2):39-52 [10381566.001]
  • [Cites] World J Gastroenterol. 2004 Dec 1;10(23):3518-21 [15526377.001]
  • [Cites] Biochem Soc Trans. 2005 Aug;33(Pt 4):672-5 [16042571.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7121-6 [16103061.001]
  • [Cites] Oncogene. 2006 Jan 5;25(1):111-21 [16247483.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):157-73 [16530701.001]
  • [Cites] J Biol Chem. 2006 Dec 22;281(51):39159-68 [17050536.001]
  • (PMID = 17935612.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / NDRG2 protein, human; 0 / RNA, Messenger; 0 / Tumor Suppressor Proteins
  • [Other-IDs] NLM/ PMC2099434
  •  go-up   go-down


84. Fariña-Sarasqueta A, Gosens MJ, Moerland E, van Lijnschoten I, Lemmens VE, Slooter GD, Rutten HJ, van den Brule AJ: TS gene polymorphisms are not good markers of response to 5-FU therapy in stage III colon cancer patients. Anal Cell Pathol (Amst); 2010;33(1):1-11
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TS gene polymorphisms are not good markers of response to 5-FU therapy in stage III colon cancer patients.
  • AIM: Although the predictive and prognostic value of thymidylate synthase (TS) expression and gene polymorphism in colon cancer has been widely studied, the results are inconclusive probably because of methodological differences.
  • With this study, we aimed to elucidate the role of TS gene polymorphisms genotyping in therapy response in stage III colon carcinoma patients treated with 5-FU adjuvant chemotherapy.
  • PATIENTS AND METHODS: 251 patients diagnosed with stage III colon carcinoma treated with surgery followed by 5-FU based adjuvant therapy were selected.
  • RESULTS: There was a positive association between tumor T stage and the VNTR genotypes (p=0.05).In both univariate and multivariate survival analysis no effects of the studied polymorphisms on survival were found.
  • CONCLUSION: We conclude that the TS VNTR and SNP do not predict response to 5-FU therapy in patients with stage III colon carcinoma.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Cell Oncol (Dordr). 2011 Aug;34(4):407-8
  • (PMID = 20966539.001).
  • [ISSN] 2210-7185
  • [Journal-full-title] Analytical cellular pathology (Amsterdam)
  • [ISO-abbreviation] Anal Cell Pathol (Amst)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 2.1.1.45 / Thymidylate Synthase; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC4605551
  •  go-up   go-down


85. Murph MM, Liu W, Yu S, Lu Y, Hall H, Hennessy BT, Lahad J, Schaner M, Helland A, Kristensen G, Børresen-Dale AL, Mills GB: Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis. PLoS One; 2009;4(5):e5583
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis.
  • Malignant ascites fluid is rich in LPA, and LPA receptors are aberrantly expressed by ovarian cancer cells, implicating LPA in the initiation and progression of ovarian cancer.
  • However, there is an absence of systematic data critically analyzing the transcriptional changes induced by LPA in ovarian cancer.
  • METHODOLOGY AND PRINCIPAL FINDINGS: In this study, gene expression profiling was used to examine LPA-mediated transcription by exogenously adding LPA to human epithelial ovarian cancer cells for 24 h to mimic long-term stimulation in the tumor microenvironment.
  • The resultant transcriptional profile comprised a 39-gene signature that closely correlated to serous epithelial ovarian carcinoma.
  • Hierarchical clustering of ovarian cancer patient specimens demonstrated that the signature is associated with worsened prognosis.
  • They have a higher frequency of stage IIIc serous carcinoma and a greater proportion is deceased.
  • Out of those seven, claudin-1, an adhesion molecule and phenotypic epithelial marker, is the only independent biomarker of serous epithelial ovarian carcinoma.
  • Knockdown of claudin-1 expression in ovarian cancer cells reduces LPA-mediated cellular adhesion, enhances suspended cells and reduces LPA-mediated migration.
  • CONCLUSIONS: The data suggest that transcriptional events mediated by LPA in the tumor microenvironment influence tumor progression through modulation of cell adhesion molecules like claudin-1 and, for the first time, report an LPA-mediated expression signature in ovarian cancer that predicts a worse prognosis.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3704-10 [10589790.001]
  • [Cites] Mol Oncol. 2008 Jun;2(1):54-69 [19081821.001]
  • [Cites] Anal Biochem. 2001 Mar15;290(2):302-13 [11237333.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] Gynecol Oncol. 2001 May;81(2):291-300 [11330965.001]
  • [Cites] Bioinformatics. 2001 Jun;17(6):520-5 [11395428.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Biochim Biophys Acta. 2002 May 23;1582(1-3):257-64 [12069836.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):1073-82 [12615725.001]
  • [Cites] Nat Rev Cancer. 2003 Aug;3(8):582-91 [12894246.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Aug;17(4):909-25, vii [12959182.001]
  • [Cites] Genome Biol. 2003;4(10):R70 [14519205.001]
  • [Cites] Nucleic Acids Res. 2003 Dec 15;31(24):e154 [14654707.001]
  • [Cites] Endocrinology. 2004 Jun;145(6):2929-40 [14988385.001]
  • [Cites] J Cell Biochem. 2004 Aug 15;92(6):1115-40 [15258897.001]
  • [Cites] Arterioscler Thromb. 1993 Nov;13(11):1662-7 [8218108.001]
  • [Cites] Biochem J. 1998 Mar 15;330 ( Pt 3):1107-14 [9494074.001]
  • [Cites] Ann Oncol. 1998 Apr;9(4):437-42 [9636836.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] Gynecol Oncol. 1998 Dec;71(3):364-8 [9887232.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 May 25;96(11):6249-54 [10339573.001]
  • [Cites] Nat Rev Cancer. 2005 May;5(5):355-66 [15864277.001]
  • [Cites] Oncogene. 2005 Jul 7;24(29):4672-87 [15940270.001]
  • [Cites] J Clin Invest. 2005 Jul;115(7):1765-76 [15965503.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9603-6 [16266975.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10602-12 [16288054.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1354-62 [16452189.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2740-8 [16510595.001]
  • [Cites] Matrix Biol. 2006 May;25(4):223-31 [16503403.001]
  • [Cites] J Biol Chem. 2006 Aug 11;281(32):22786-93 [16782709.001]
  • [Cites] Eur J Cancer. 2006 Nov;42(16):2846-54 [16996261.001]
  • [Cites] Gynecol Oncol. 2006 Nov;103(2):591-8 [16797678.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Am J Obstet Gynecol. 2007 Mar;196(3):245.e1-11 [17346539.001]
  • [Cites] Am J Clin Pathol. 2007 Jun;127(6):928-37 [17509990.001]
  • [Cites] Expert Rev Mol Med. 2007;9(28):1-18 [17935635.001]
  • [Cites] Hum Pathol. 2008 May;39(5):747-57 [18439941.001]
  • [Cites] Adv Exp Med Biol. 2008;617:23-40 [18497028.001]
  • [Cites] Clin Cancer Res. 2008 Aug 15;14(16):5198-208 [18698038.001]
  • [Cites] Biochim Biophys Acta. 2008 Sep;1781(9):547-57 [18501205.001]
  • [Cites] J Natl Cancer Inst. 2008 Nov 19;100(22):1630-42 [19001604.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2482-91 [10873103.001]
  • (PMID = 19440550.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA099031; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / P50 CA098258
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CLDN1 protein, human; 0 / Claudin-1; 0 / Lysophospholipids; 0 / Membrane Proteins; 22002-87-5 / lysophosphatidic acid
  • [Other-IDs] NLM/ PMC2679144
  •  go-up   go-down


86. Feng HY, Li DC, Lou RC, Zhu Y, Liu LY: [Preoperative chemoradiotherapy as neoadjuvant therapy for 35 patients with locally advanced lower rectal carcinoma]. Zhonghua Wei Chang Wai Ke Za Zhi; 2005 Mar;8(2):125-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Preoperative chemoradiotherapy as neoadjuvant therapy for 35 patients with locally advanced lower rectal carcinoma].
  • OBJECTIVE: To explore the effect of combined preoperative chemotherapy with radiotherapy on locally advanced lower rectal carcinoma.
  • METHODS: Thirty- five patients with locally advanced lower rectal carcinoma were received a new regimen of combined preoperative chemotherapy with radiotherapy.
  • RESULTS: After neoadjuvant therapy,all patients underwent surgical resection with complete pathologic response in 7 patients,average tumor size decrease of in 34.4%, tumor stage decrease in 65.7% o f patients and nodal- negative change rate of 55.6%.
  • Radical resection was per formed in 34 patients,in whom 18 patients received abdominoperineal resection(AP R) and 16 patients received sphincter- preserving surgery with 45.7% of anal preservation rate.
  • CONCLUSION: Combined preoperative chemotherapy with radiotherapy is a better neoadjuvant therapy for lower advanced rectal cancer,which can decrease tumor stage,improve resectability and anal sphincter preservation rate,therefore ,this new neoadjuvant therapy with tolerable toxicity will has a promising application in the clinical setting.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16155821.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


87. Rubio CA, Nilsson PJ: Squamous-cell carcinoma of the anus with high intratumoral lymphocytosis and its clinical implications. Anticancer Res; 2008 Jul-Aug;28(4C):2469-72
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous-cell carcinoma of the anus with high intratumoral lymphocytosis and its clinical implications.
  • BACKGROUND: It has been claimed that patients with squamous cell carcinoma of the anal canal (SCCAC) showing intraepithelial lymphocytes have a poor prognosis.
  • All these 8 patients with SCCAC/HTIL had clinical stage II and III while these stages comprised 83% of the remaining SCCAC cases.
  • CONCLUSION: Despite the 8 SCCAC/HTIL patients having a more advanced clinical stage than the remaining 269 SCCAC patients, these 8 patients had longer survival.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. Lymphocytes, Tumor-Infiltrating / pathology. Lymphocytosis / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18751436.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


88. Ren N, Ye QH, Qin LX, Zhang BH, Liu YK, Tang ZY: Circulating DNA level is negatively associated with the long-term survival of hepatocellular carcinoma patients. World J Gastroenterol; 2006 Jun 28;12(24):3911-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating DNA level is negatively associated with the long-term survival of hepatocellular carcinoma patients.
  • AIM: To quantify the circulating DNA in plasma from patients with hepatocellular carcinoma (HCC) and to evaluate its prognostic value.
  • The circulating DNA level was closely associated with tumor size (P = 0.008) and TNM stage (P = 0.040), negatively associated with the 3-year disease-free survival (DFS) (P = 0.017) and overall survival (OS) (P = 0.001).
  • [MeSH-major] Carcinoma, Hepatocellular / blood. Carcinoma, Hepatocellular / pathology. DNA, Neoplasm / blood. Liver Neoplasms / blood. Liver Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):1047-52 [12631605.001]
  • [Cites] Int J Cancer. 2003 Jan 10;103(2):149-52 [12455027.001]
  • [Cites] N Engl J Med. 2004 Jun 10;350(24):2461-70 [15190138.001]
  • [Cites] Ann N Y Acad Sci. 2004 Jun;1022:17-24 [15251934.001]
  • [Cites] Cancer Res. 1977 Mar;37(3):646-50 [837366.001]
  • [Cites] Oncology. 1989;46(5):318-22 [2779946.001]
  • [Cites] Cancer. 1990 Nov 15;66(10):2174-9 [2171748.001]
  • [Cites] Mol Med. 1995 May;1(4):344-65 [8521292.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):578-84 [10080602.001]
  • [Cites] Hepatology. 1999 Oct;30(4):1027-36 [10498656.001]
  • [Cites] Nature. 1953 Apr 25;171(4356):737-8 [13054692.001]
  • [Cites] Anal Biochem. 1999 Dec 1;276(1):59-64 [10585744.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1805-11 [11078757.001]
  • [Cites] Transfusion. 2001 Feb;41(2):276-82 [11239235.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4675-8 [11406535.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5723-6 [11479206.001]
  • [Cites] Clin Chem. 2001 Sep;47(9):1607-13 [11514393.001]
  • [Cites] CA Cancer J Clin. 2001 Jan-Feb;51(1):15-36 [11577478.001]
  • [Cites] World J Gastroenterol. 2002 Apr;8(2):193-9 [11925590.001]
  • [Cites] World J Gastroenterol. 2001 Aug;7(4):445-54 [11819809.001]
  • [Cites] Anticancer Res. 2002 Jan-Feb;22(1A):421-5 [12017326.001]
  • [Cites] Br J Cancer. 2002 Dec 2;87(12):1449-53 [12454776.001]
  • [Cites] Hepatogastroenterology. 2003 Sep-Oct;50(53):1579-82 [14571790.001]
  • (PMID = 16804981.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ PMC4087944
  •  go-up   go-down


89. Nese N, Kesici G, Lekili M, Isisag A: Urachal urothelial carcinoma diagnosed at a radical prostatectomy operation: a case report. Anal Quant Cytol Histol; 2010 Jun;32(3):174-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urachal urothelial carcinoma diagnosed at a radical prostatectomy operation: a case report.
  • CONCLUSION: The origin of urachal carcinomas is usually obscured as it is a highly invasive carcinoma.
  • Although the stage was advanced, the tumor was detected before urachal remnants were destroyed.

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20701072.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Page BR, McDonald T, Gagnon P, Lu K, Thomas CR: A unique case of Hajdu-Cheney syndrome and squamous cell carcinoma of the anus. Colorectal Dis; 2009 Jun;11(5):535-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A unique case of Hajdu-Cheney syndrome and squamous cell carcinoma of the anus.
  • No articles exist in the current literature describing a case of HCS with concurrent carcinoma.
  • Here, we present a case of a 54-year-old nonimmune compromised woman with multiple stigmata of HCS and recently diagnosed anal squamous cell carcinoma.
  • METHOD: This is a case report of HCS and stage T3N0 squamous cell carcinoma of the anus.
  • CONCLUSIONS: We present a patient with HCS who developed anal squamous cell carcinoma.
  • The mechanism of HCS, which is still unknown, may either make patients more susceptible to carcinoma or may just be a reflection of the normal incidence of anal squamous cell carcinoma given attributable risk factors.
  • [MeSH-major] Anus Neoplasms / complications. Carcinoma, Squamous Cell / complications. Hajdu-Cheney Syndrome / complications


91. Pawlik TM, Hawke DH, Liu Y, Krishnamurthy S, Fritsche H, Hunt KK, Kuerer HM: Proteomic analysis of nipple aspirate fluid from women with early-stage breast cancer using isotope-coded affinity tags and tandem mass spectrometry reveals differential expression of vitamin D binding protein. BMC Cancer; 2006;6:68
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic analysis of nipple aspirate fluid from women with early-stage breast cancer using isotope-coded affinity tags and tandem mass spectrometry reveals differential expression of vitamin D binding protein.
  • We sought to determine whether ICAT technology could quantify and identify differential expression of tumor-specific proteins in nipple aspirate fluid (NAF) from the tumor-bearing and contralateral disease-free breasts of patients with unilateral early-stage breast cancer.
  • METHODS: Paired NAF samples from 18 women with stage I or II unilateral invasive breast carcinoma and 4 healthy volunteers were analyzed using ICAT labeling, sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE), liquid chromatography, and MS.
  • Western blot analysis of NAF from an independent sample set from 12 women (8 with early-stage breast cancer and 4 healthy volunteers) was also performed.
  • Western blot analysis of pooled samples of NAF from healthy volunteers versus NAF from women with breast cancer confirmed the overexpression of vitamin D-binding protein in tumor-bearing breasts.
  • Proteomic screening techniques using ICAT and NAF may be used to find markers for diagnosis of breast cancer.
  • [MeSH-minor] Blotting, Western. Body Fluids / metabolism. Carbon Isotopes. Carcinoma / diagnosis. Carcinoma / metabolism. Chromatography, Liquid. Female. Humans. Middle Aged. Peptides / analysis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proteomics. 2003 Oct;3(10):1863-73 [14625848.001]
  • [Cites] Mol Cell Proteomics. 2003 Nov;2(11):1198-204 [14506205.001]
  • [Cites] Bioconjug Chem. 2004 Mar-Apr;15(2):380-8 [15025535.001]
  • [Cites] J Biol Chem. 2004 Apr 2;279(14):14129-39 [14729674.001]
  • [Cites] J Biol Chem. 2004 May 7;279(19):20127-36 [14988394.001]
  • [Cites] Biochem Soc Trans. 2004 Jun;32(Pt3):520-3 [15157176.001]
  • [Cites] J Proteome Res. 2004 May-Jun;3(3):604-12 [15253443.001]
  • [Cites] Genome Biol. 2004;5(8):R54 [15287976.001]
  • [Cites] World J Gastroenterol. 2004 Sep 15;10(18):2652-6 [15309713.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6402-9 [15374947.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Oct;130(10):615-22 [15243804.001]
  • [Cites] Mol Cell Proteomics. 2004 Oct;3(10):960-9 [15238602.001]
  • [Cites] J Natl Cancer Inst. 1977 Oct;59(4):1073-80 [903989.001]
  • [Cites] Lancet. 1979 Dec 22-29;2(8156-8157):1335-6 [92676.001]
  • [Cites] Cancer Res. 1980 Dec;40(12):4764-7 [6254651.001]
  • [Cites] Biochem Biophys Res Commun. 1981 Aug 31;101(4):1131-8 [6272774.001]
  • [Cites] Cancer Res. 1981 Dec;41(12 Pt 1):5121-4 [6272989.001]
  • [Cites] Cancer Res. 1984 Apr;44(4):1677-81 [6322984.001]
  • [Cites] Nat Biotechnol. 1999 Jul;17(7):676-82 [10404161.001]
  • [Cites] Nat Biotechnol. 1999 Oct;17(10):994-9 [10504701.001]
  • [Cites] FEBS J. 2005 Jan;272(1):2-15 [15634327.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Feb 5;815(1-2):215-25 [15652811.001]
  • [Cites] Breast Cancer Res Treat. 2005 Jan;89(2):149-57 [15692757.001]
  • [Cites] Int J Cancer. 2005 May 1;114(5):791-6 [15609313.001]
  • [Cites] Mol Biotechnol. 2005 Mar;29(3):233-44 [15767701.001]
  • [Cites] Proteomics. 2005 May;5(7):1797-805 [15825149.001]
  • [Cites] Nat Genet. 2003 Mar;33(3):349-55 [12590263.001]
  • [Cites] N Engl J Med. 1992 Jul 30;327(5):319-28 [1620171.001]
  • [Cites] Breast Cancer Res Treat. 1994;31(2-3):357-70 [7881112.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Dec;5(12):967-70 [8959318.001]
  • [Cites] Anal Chem. 1997 Apr 15;69(8):1518-24 [9109352.001]
  • [Cites] Br J Cancer. 1997;76(4):494-501 [9275027.001]
  • [Cites] N Engl J Med. 1998 Apr 16;338(16):1089-96 [9545356.001]
  • [Cites] Lancet. 2000 Aug 12;356(9229):567 [10950239.001]
  • [Cites] Curr Opin Biotechnol. 2000 Aug;11(4):413-8 [10975463.001]
  • [Cites] Curr Opin Chem Biol. 2000 Oct;4(5):489-94 [11006534.001]
  • [Cites] Ann N Y Acad Sci. 2000;923:312-5 [11193768.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1462-7 [11230492.001]
  • [Cites] Breast Cancer Res. 2000;2(2):92-9 [11250698.001]
  • [Cites] Anal Chem. 2001 Mar 1;73(5):978-86 [11289445.001]
  • [Cites] EMBO J. 2001 Sep 3;20(17):4782-93 [11532942.001]
  • [Cites] Nat Biotechnol. 2001 Oct;19(10):946-51 [11581660.001]
  • [Cites] J Am Soc Mass Spectrom. 2001 Dec;12(12):1238-46 [11766750.001]
  • [Cites] Dis Markers. 2001;17(4):301-7 [11790897.001]
  • [Cites] J Mass Spectrom. 2002 Jan;37(1):1-14 [11813306.001]
  • [Cites] Breast J. 2001 Nov-Dec;7(6):378-87 [11843848.001]
  • [Cites] Lancet. 2002 Feb 16;359(9306):572-7 [11867112.001]
  • [Cites] Nat Biotechnol. 2002 May;20(5):512-5 [11981568.001]
  • [Cites] Biochemistry. 2002 May 28;41(21):6714-22 [12022875.001]
  • [Cites] EMBO J. 2002 Oct 1;21(19):5088-96 [12356725.001]
  • [Cites] Curr Opin Chem Biol. 2002 Oct;6(5):666-75 [12413552.001]
  • [Cites] Cancer. 2002 Dec 1;95(11):2276-82 [12436432.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6740-9 [12438275.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):749-54 [12576445.001]
  • [Cites] Anal Chem. 2003 May 1;75(9):2159-65 [12720356.001]
  • [Cites] Breast Cancer Res. 2003;5(4):R82-7 [12817998.001]
  • [Cites] J Am Soc Mass Spectrom. 2003 Jul;14(7):696-703 [12837591.001]
  • [Cites] Breast Cancer Res. 2003;5(6):320-8 [14580250.001]
  • [Cites] Int J Biol Markers. 2003 Oct-Dec;18(4):241-72 [14756541.001]
  • (PMID = 16542425.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carbon Isotopes; 0 / Peptides; 0 / Vitamin D-Binding Protein
  • [Other-IDs] NLM/ PMC1431555
  •  go-up   go-down


92. Aoki H, Ishidoya S, Ito A, Endoh M, Shimazui T, Arai Y: Experience of the treatment with gemcitabine, docetaxel, and carboplatin (GDC) chemotherapy for patients with small-cell carcinoma of the prostate. Int J Urol; 2006 Sep;13(9):1254-8
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Experience of the treatment with gemcitabine, docetaxel, and carboplatin (GDC) chemotherapy for patients with small-cell carcinoma of the prostate.
  • Small-cell carcinoma of the prostate (SCCP) is a rare entity.
  • Case 1 involved a 53-year-old man diagnosed with SCCP after receiving hormone therapy for prostate cancer (stage D1).
  • Initially the primary site reduced according with a decline of neuro-specific enolase and with relief of the symptoms; however, bone disease occurred and he died of cancer 13 months after diagnosis of SCCP.
  • Case 2 involved a 69-year-old man complaining of severe anal pain.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / drug therapy. Prostatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16984566.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin
  •  go-up   go-down


93. Masljankov S, Jaramov N: [Analysis of oncologic results and quality of life after radical treatment of rectum carcinoma in Specialized Oncological Hospital of Veliko Tarnovo]. Khirurgiia (Sofiia); 2009;(4-5):10-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of oncologic results and quality of life after radical treatment of rectum carcinoma in Specialized Oncological Hospital of Veliko Tarnovo].
  • INTRODUCTION: Rectum carcinoma is an increasing problem with a great variety of possible operative decisions.
  • The aim of this study is to present and analyze the oncologic and initial quality of life data of operated with rectum carcinoma in Specialized Oncological Hospital of Veliko Tarnovo.
  • 179 patients ware analyzed in groups according their sex, age, stage and type of operation.
  • RESULTS: The operative intervention types ware analyzed, according to anal verge distance: 63.4% sphincterspared.
  • CONCLUSION: We have better onologic and functional result in early stages and at higher localization of rectum carcinoma disease.
  • [MeSH-major] Carcinoma / surgery. Quality of Life. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20506798.001).
  • [ISSN] 0450-2167
  • [Journal-full-title] Khirurgii︠a︡
  • [ISO-abbreviation] Khirurgiia (Sofiia)
  • [Language] bul
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Bulgaria
  •  go-up   go-down


94. Edelman S, Johnstone PA: Combined modality therapy for HIV-infected patients with squamous cell carcinoma of the anus: outcomes and toxicities. Int J Radiat Oncol Biol Phys; 2006 Sep 1;66(1):206-11
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined modality therapy for HIV-infected patients with squamous cell carcinoma of the anus: outcomes and toxicities.
  • PURPOSE: We report toxicity and survival data of human immunodeficiency virus (HIV)-infected men with anal carcinoma treated with combined modality therapy (CMT) of radiotherapy and concurrent chemotherapy.
  • METHODS AND MATERIALS: A retrospective review was performed on the records of 17 HIV-positive patients with anal squamous cell carcinoma treated with CMT at our institution between 1991 and 2004.
  • Fourteen of 15 patients with Stage I-III disease had a complete response; 2 complete responders subsequently had a relapse in the anorectum.
  • For patients with Stage I-III disease, survival at last follow-up by low CD4 count (<200) vs. high count (>200) was 4 of 7 vs. 7 of 8, respectively; significant acute toxicities developed in 4 of 8 vs. 6 of 9, respectively.
  • CONCLUSION: For HIV patients with anal carcinoma, CMT yields reasonable local control with significant acute complications.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. HIV Infections / complications

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16904522.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NIMHD NIH HHS / MD / 5P60-MD000525
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


95. Kouzu Y, Uzawa K, Koike H, Saito K, Nakashima D, Higo M, Endo Y, Kasamatsu A, Shiiba M, Bukawa H, Yokoe H, Tanzawa H: Overexpression of stathmin in oral squamous-cell carcinoma: correlation with tumour progression and poor prognosis. Br J Cancer; 2006 Mar 13;94(5):717-23
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of stathmin in oral squamous-cell carcinoma: correlation with tumour progression and poor prognosis.
  • Our previous study using proteomic profiling showed that significant upregulation of stathmin occurs in oral squamous-cell carcinoma (OSCC)-derived cell lines.
  • Moreover, stathmin expression status was correlated with the TNM stage grading.
  • These results suggest that expression of stathmin could contribute to cancer progression/prognosis, and that stathmin may have potential as a biomarker and a therapeutic target for OSCC.
  • [MeSH-major] Carcinoma, Squamous Cell / genetics. Mouth Neoplasms / genetics. Stathmin / biosynthesis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Oral squamous cell carcinoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1993 Oct;8(10):2869-72 [8397372.001]
  • [Cites] J Biol Chem. 1991 Nov 5;266(31):21004-10 [1939149.001]
  • [Cites] Prostate. 1995 Aug;27(2):102-9 [7638082.001]
  • [Cites] Cell. 1996 Feb 23;84(4):623-31 [8598048.001]
  • [Cites] Biotechnol Genet Eng Rev. 1996;13:19-50 [8948108.001]
  • [Cites] Cell Signal. 1997 May-Jun;9(3-4):249-55 [9218124.001]
  • [Cites] Br J Cancer. 1998 Sep;78(6):701-9 [9743287.001]
  • [Cites] J Clin Oncol. 2005 Jan 10;23(2):346-56 [15637397.001]
  • [Cites] Br J Cancer. 2005 May 23;92(10):1915-21 [15870709.001]
  • [Cites] Int J Oncol. 2005 Jul;27(1):59-67 [15942644.001]
  • [Cites] Int J Mol Med. 2005 Aug;16(2):269-73 [16012760.001]
  • [Cites] Int J Cancer. 2006 Feb 1;118(3):704-13 [16094606.001]
  • [Cites] Mol Carcinog. 2000 Mar;27(3):158-65 [10708477.001]
  • [Cites] FEBS Lett. 2000 Mar 10;469(2-3):155-8 [10713262.001]
  • [Cites] Electrophoresis. 2000 Apr;21(6):1202-9 [10786892.001]
  • [Cites] Nature. 2000 Jun 15;405(6788):837-46 [10866210.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3537-41 [10910066.001]
  • [Cites] Br J Cancer. 2000 Aug;83(3):311-8 [10917544.001]
  • [Cites] Anal Biochem. 2000 Aug 15;284(1):49-59 [10933855.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):3949-56 [11051243.001]
  • [Cites] Cancer Invest. 2000;18(8):722-30 [11107442.001]
  • [Cites] Curr Opin Mol Ther. 2000 Dec;2(6):633-42 [11249740.001]
  • [Cites] Nat Rev Genet. 2000 Oct;1(1):48-56 [11262874.001]
  • [Cites] Cancer. 2001 Apr 15;91(8):1494-9 [11301397.001]
  • [Cites] Mt Sinai J Med. 2002 Oct;69(5):299-304 [12415323.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6598-605 [12438255.001]
  • [Cites] J Dent Res. 2003 Aug;82(8):607-11 [12885844.001]
  • [Cites] Int J Cancer. 2004 Jun 10;110(2):225-31 [15069686.001]
  • [Cites] J Cell Biochem. 2004 Oct 1;93(2):242-50 [15368352.001]
  • [Cites] J Biol Chem. 1983 Sep 10;258(17):10786-93 [6577004.001]
  • [Cites] J Biol Chem. 1988 Sep 15;263(26):12813-5 [3417633.001]
  • [Cites] Leukemia. 1993 Oct;7(10):1538-46 [8412315.001]
  • (PMID = 16495930.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / STMN1 protein, human; 0 / Stathmin
  • [Other-IDs] NLM/ PMC2361217
  •  go-up   go-down


96. Hegele A, Hofmann R, Kosche B, Kropf J: Evaluation of cellular fibronectin plasma levels as a useful staging tool in different stages of transitional cell carcinoma of the bladder and renal cell carcinoma. Biomark Insights; 2007 Feb 07;2:1-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of cellular fibronectin plasma levels as a useful staging tool in different stages of transitional cell carcinoma of the bladder and renal cell carcinoma.
  • Reliable markers for both renal cell carcinoma (RCC) and transitional cell carcinoma of the bladder (TCC) are lacking.During tumor progression and invasion components of extracellular matrix (ECM) are degraded and parts of these different components are detectable in plasma.
  • Similar results were found in RCC with significant elevated cFN levels in metastatic RCC (p < 0.005) compared to localized stage of disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biomarkers. 2005 Jul-Aug;10(4):258-94 [16191485.001]
  • [Cites] J Urol. 2005 Nov;174(5):1771-5; discussion 1775-6 [16217281.001]
  • [Cites] Cancer. 2005 Jul 1;104(1):30-5 [15912517.001]
  • [Cites] Lancet Oncol. 2005 Sep;6(9):678-86 [16129368.001]
  • [Cites] Br J Cancer. 1997;76(6):777-83 [9310245.001]
  • [Cites] Eur Urol. 1997;31(1):40-8 [9032533.001]
  • [Cites] Int J Cancer. 1996 Nov 4;68(3):364-71 [8903479.001]
  • [Cites] Exp Cell Res. 1995 Nov;221(1):83-91 [7589259.001]
  • [Cites] Cancer Metastasis Rev. 1995 Sep;14(3):173-89 [8548867.001]
  • [Cites] J Hepatol. 1995;22(2 Suppl):77-81 [7665854.001]
  • [Cites] Br J Cancer. 1995 Mar;71(3):578-82 [7880741.001]
  • [Cites] Clin Chem. 1995 Sep;41(9):1283-7 [7656438.001]
  • [Cites] J Urol. 1993 Feb;149(2):268-71 [8426398.001]
  • [Cites] Jpn J Cancer Res. 1992 Dec;83(12):1327-33 [1483947.001]
  • [Cites] Urol Clin North Am. 1992 Aug;19(3):429-33 [1636228.001]
  • [Cites] Anal Biochem. 1991 Aug 15;197(1):258-65 [1952074.001]
  • [Cites] J Cell Biol. 1986 Nov;103(5):1671-7 [3023390.001]
  • [Cites] Arch Dermatol. 1988 Feb;124(2):221-5 [3341802.001]
  • [Cites] J Cell Biol. 1982 Nov;95(2 Pt 1):369-77 [6128348.001]
  • [Cites] Tumour Biol. 2004 May-Jun;25(3):111-6 [15361707.001]
  • [Cites] J Urol. 2004 Oct;172(4 Pt 1):1496-500 [15371878.001]
  • [Cites] Urol Res. 2003 Feb;30(6):363-6 [12599015.001]
  • [Cites] Mod Pathol. 2002 Aug;15(8):826-30 [12181267.001]
  • [Cites] Urol Res. 2002 May;30(2):126-9 [12086018.001]
  • [Cites] Eur Urol. 2001 Mar;39(3):292-9 [11275722.001]
  • [Cites] Int J Cancer. 2002 Apr 20;98(6):889-94 [11948468.001]
  • [Cites] Thromb Res. 2002 Jan 1;105(1):37-41 [11864705.001]
  • [Cites] J Urol. 2002 Jan;167(1):80-3 [11743280.001]
  • [Cites] Curr Probl Cancer. 2001 Jul-Aug;25(4):219-78 [11514784.001]
  • [Cites] J Urol. 2001 Aug;166(2):470-5 [11458049.001]
  • [Cites] Clin Cancer Res. 2000 Sep;6(9):3585-94 [10999749.001]
  • [Cites] Urol Int. 2000;64(4):198-201 [10895085.001]
  • [Cites] Cancer Lett. 2000 Jul 31;155(2):199-205 [10822136.001]
  • [Cites] J Urol. 2000 Feb;163(2):408-17 [10647643.001]
  • [Cites] Clin Chim Acta. 2006 Oct;372(1-2):83-93 [16730689.001]
  • [Cites] J Thromb Haemost. 2006 Jul;4(7):1461-9 [16839338.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2006 Jun;26(6):1193-5 [16709950.001]
  • [Cites] Curr Pharm Des. 2005;11(7):881-91 [15777241.001]
  • (PMID = 19662188.001).
  • [Journal-full-title] Biomarker insights
  • [ISO-abbreviation] Biomark Insights
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2717843
  • [Keywords] NOTNLM ; Biological markers / Extracellular matrix / Invasion / TRFIA / tumor progression
  •  go-up   go-down


97. Vironen J, Juhola M, Kairaluoma M, Jantunen I, Kellokumpu I: Tumour regression grading in the evaluation of tumour response after different preoperative radiotherapy treatments for rectal carcinoma. Int J Colorectal Dis; 2005 Sep;20(5):440-5
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumour regression grading in the evaluation of tumour response after different preoperative radiotherapy treatments for rectal carcinoma.
  • BACKGROUND AND AIMS: Preoperative radiotherapy (PRT) for rectal carcinoma has been shown to cause tumour regression and increase local control and patient survival.
  • METHODS: Depending on the tumour stage (uT), as defined by preoperative endorectal ultrasound (ERUS), fixity and distance from the anal verge, 126 patients with rectal cancer underwent either surgery alone, or received short-course 25-Gy radiotherapy or long-course 50-Gy radiotherapy combined with 5-fluorouracil (5-FU) before surgery.
  • TRG in each group was assessed and compared with the downstaging, defined as a change in preoperative uT stage and pathologic stage (pT).
  • In contrast, T-stage downstaging was similar in both groups and did not correlate with the TRG results (p=0.05).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15856263.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


98. Nair KS, Naidoo R, Chetty R: Expression of cell adhesion molecules in oesophageal carcinoma and its prognostic value. J Clin Pathol; 2005 Apr;58(4):343-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of cell adhesion molecules in oesophageal carcinoma and its prognostic value.
  • Oesophageal carcinoma remains a disease of poor prognosis.
  • Surgical cure rates are compromised by the fact that most patients are diagnosed at a late stage of disease because of the delayed onset of symptoms, by which time metastases and organ infiltration may have already occurred.
  • This review provides a brief description of five families of CAMs (cadherins, integrins, CD44, immunoglobulin superfamily, and selectins) and highlights their altered expression in relation both to prognosis and tumour behaviour in squamous cell carcinoma and adenocarcinoma of the oesophagus.
  • [MeSH-minor] Adenocarcinoma / chemistry. Antigens, CD44 / analysis. Cadherins / analysis. Carcinoma, Squamous Cell / chemistry. Humans. Integrins / analysis. Neoplasm Metastasis. Prognosis. Selectins / analysis

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 1998 Jan;32(1):7-14 [9522210.001]
  • [Cites] J Cell Physiol. 1998 Sep;176(3):482-94 [9699501.001]
  • [Cites] Cancer. 1998 Sep 1;83(5):858-66 [9731887.001]
  • [Cites] Chest. 1999 Dec;116(6 Suppl):463S-465S [10619509.001]
  • [Cites] Mol Pathol. 1999 Aug;52(4):189-96 [10694938.001]
  • [Cites] Mol Pathol. 1999 Aug;52(4):208-13 [10694941.001]
  • [Cites] Int J Oncol. 2000 Apr;16(4):677-82 [10717234.001]
  • [Cites] Int J Oncol. 2000 Apr;16(4):725-9 [10717240.001]
  • [Cites] Genes Dev. 2000 Aug 1;14(15):1837-51 [10921899.001]
  • [Cites] Br J Surg. 2000 Aug;87(8):992-1005 [10931041.001]
  • [Cites] J Cell Biol. 2000 Aug 7;150(3):567-80 [10931868.001]
  • [Cites] Int J Oncol. 2000 Oct;17(4):701-5 [10995880.001]
  • [Cites] Breast Cancer. 2000 Jan;7(1):19-26 [11029766.001]
  • [Cites] Cell Biol Int. 2001;25(1):61-9 [11237409.001]
  • [Cites] Clin Chem. 2001 Apr;47(4):624-30 [11274010.001]
  • [Cites] Oncol Rep. 2001 Sep-Oct;8(5):981-5 [11496302.001]
  • [Cites] Clin Cancer Res. 2001 Nov;7(11):3519-25 [11705871.001]
  • [Cites] J Clin Invest. 2002 Apr;109(8):999-1006 [11956235.001]
  • [Cites] J Cell Biol. 1991 Sep;114(5):1059-68 [1874786.001]
  • [Cites] Annu Rev Biochem. 1991;60:155-90 [1883195.001]
  • [Cites] J Clin Lab Anal. 1991;5(5):344-66 [1941355.001]
  • [Cites] J Cell Biol. 1991 Dec;115(6):1751-61 [1757472.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Mar 15;89(6):2292-6 [1372439.001]
  • [Cites] Cell. 1992 Apr 3;69(1):11-25 [1555235.001]
  • [Cites] Cell. 1992 Apr 17;69(2):225-36 [1568244.001]
  • [Cites] J Pathol. 1992 May;167(1):77-82 [1625062.001]
  • [Cites] J Pathol. 1992 Jun;167(2):187-91 [1378891.001]
  • [Cites] Cell. 1992 Jul 24;70(2):293-301 [1638632.001]
  • [Cites] Lancet. 1992 Oct 31;340(8827):1053-8 [1357452.001]
  • [Cites] Br J Cancer. 1992 Oct;66(4):629-34 [1384639.001]
  • [Cites] J Cell Biol. 1993 Feb;120(3):577-85 [8381117.001]
  • [Cites] Lancet. 1993 Mar 20;341(8847):725-6 [8095628.001]
  • [Cites] Am J Pathol. 1993 Apr;142(4):981-6 [7682766.001]
  • [Cites] Am J Pathol. 1993 Apr;142(4):987-93 [7682767.001]
  • [Cites] J Surg Oncol. 1993 Jun;53(2):78-83 [8501910.001]
  • [Cites] Br J Cancer. 1993 Jul;68(1):122-4 [7686390.001]
  • [Cites] J Cell Biol. 1993 Jul;122(2):431-42 [8320265.001]
  • [Cites] Br J Cancer. 1993 Aug;68(2):428-32 [8347502.001]
  • [Cites] Cancer Res. 1993 Sep 15;53(18):4197-203 [7689929.001]
  • [Cites] J Biol Chem. 1993 Oct 25;268(30):22883-94 [8226797.001]
  • [Cites] Nature. 1993 Dec 16;366(6456):630-1 [7505052.001]
  • [Cites] Nature. 1993 Dec 16;366(6456):695-8 [7505053.001]
  • [Cites] Cancer Res. 1994 Jan 1;54(1):291-6 [8261454.001]
  • [Cites] Cell. 1994 Jan 28;76(2):301-14 [7507411.001]
  • [Cites] J Cell Biol. 1994 Feb;124(4):589-600 [8106556.001]
  • [Cites] Cancer. 1994 Mar 1;73(5):1324-31 [7906606.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):3007-10 [8187090.001]
  • [Cites] J Cell Biol. 1994 Jun;125(6):1327-40 [8207061.001]
  • [Cites] J Cell Biol. 1994 Jul;126(2):391-401 [7518464.001]
  • [Cites] Semin Oncol. 1994 Aug;21(4):425-30 [8042040.001]
  • [Cites] J Cell Biol. 1994 Aug;126(4):1099-109 [7519619.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Aug 16;91(17):8263-7 [8058792.001]
  • [Cites] Blood. 1994 Oct 1;84(7):2068-101 [7522621.001]
  • [Cites] J Biol Chem. 1994 Oct 28;269(43):26602-5 [7929388.001]
  • [Cites] J Cell Physiol. 1997 Oct;173(1):54-63 [9326449.001]
  • [Cites] J Pathol. 1997 Jul;182(3):331-8 [9349237.001]
  • [Cites] Blood. 1997 Nov 15;90(10):4039-45 [9354673.001]
  • [Cites] Int J Cancer. 1997 Dec 19;74(6):582-7 [9421352.001]
  • [Cites] Am J Pathol. 1998 Jan;152(1):135-44 [9422531.001]
  • [Cites] J Cell Biol. 1997 Jun 16;137(6):1421-31 [9182672.001]
  • [Cites] Cancer. 1998 Sep 15;83(6):1074-80 [9740070.001]
  • [Cites] Clin Cancer Res. 1996 Jul;2(7):1097-102 [9816273.001]
  • [Cites] Cell. 1996 Oct 18;87(2):175-85 [8861902.001]
  • [Cites] Science. 1996 Nov 15;274(5290):1123-33 [8895455.001]
  • [Cites] Dev Biol. 1996 Dec 15;180(2):402-12 [8954713.001]
  • [Cites] Br J Surg. 1996 Nov;83(11):1608-14 [9014688.001]
  • [Cites] Clin Cancer Res. 1998 Feb;4(2):407-10 [9516929.001]
  • [Cites] J Clin Invest. 1997 Jul 1;100(1):1-5 [9202049.001]
  • [Cites] EMBO J. 1997 Jul 1;16(13):3797-804 [9233789.001]
  • [Cites] J Pathol. 1998 Sep;186(1):1-2 [9875132.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jan 5;96(1):139-44 [9874785.001]
  • [Cites] J Cell Biol. 1999 Mar 22;144(6):1311-22 [10087272.001]
  • [Cites] Semin Cancer Biol. 1999 Apr;9(2):67-81 [10202129.001]
  • [Cites] Am J Med. 1999 Apr;106(4):467-76 [10225251.001]
  • [Cites] Am J Pathol. 1999 Apr;154(4):965-73 [10233832.001]
  • [Cites] Hepatogastroenterology. 1999 Mar-Apr;46(26):938-43 [10370643.001]
  • [Cites] Cell Growth Differ. 1999 Jun;10(6):369-76 [10392898.001]
  • [Cites] J Biol Chem. 1999 Jul 23;274(30):21409-15 [10409703.001]
  • [Cites] Curr Opin Cell Biol. 1999 Oct;11(5):591-6 [10508646.001]
  • [Cites] J Exp Med. 1965 Mar 1;121:439-62 [14270243.001]
  • [Cites] Anticancer Res. 2002 May-Jun;22(3):1849-57 [12168881.001]
  • [Cites] J Cell Biol. 2002 Sep 2;158(5):953-65 [12213839.001]
  • [Cites] World J Gastroenterol. 2003 Feb;9(2):225-32 [12532436.001]
  • [Cites] Surgery. 2003 Feb;133(2):162-9 [12605177.001]
  • [Cites] Anticancer Res. 2003 Jan-Feb;23(1A):161-5 [12680208.001]
  • [Cites] J Neurosurg. 2003 May;98(5):1084-93 [12744370.001]
  • [Cites] Anticancer Res. 2003 Nov-Dec;23(6a):4435-42 [14666731.001]
  • [Cites] Cancer Res. 1986 Jan;46(1):1-7 [2998604.001]
  • [Cites] J Cell Biol. 1987 May;104(5):1361-74 [3553211.001]
  • [Cites] J Exp Med. 1987 Oct 1;166(4):1125-31 [3655655.001]
  • [Cites] J Pathol. 1988 Jul;155(3):207-12 [3411381.001]
  • [Cites] Development. 1988 Apr;102(4):639-55 [3048970.001]
  • [Cites] Biochim Biophys Acta. 1988 Nov 15;948(2):175-224 [3052592.001]
  • [Cites] Cell. 1989 Apr 21;57(2):327-34 [2702691.001]
  • [Cites] Science. 1989 Dec 8;246(4935):1303-6 [2588007.001]
  • [Cites] Science. 1990 Jan 5;247(4938):49-56 [2294591.001]
  • [Cites] Cancer Res. 1990 Feb 15;50(4):1271-8 [1967552.001]
  • [Cites] J Cell Biol. 1990 Feb;110(2):349-57 [2153683.001]
  • [Cites] Cell. 1990 Feb 23;60(4):577-84 [1689216.001]
  • [Cites] Cancer Metastasis Rev. 1989 Dec;8(3):263-80 [2697474.001]
  • [Cites] Science. 1990 Mar 9;247(4947):1219-22 [1690453.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jun;87(11):4246-50 [2349235.001]
  • [Cites] Cell. 1990 Jun 29;61(7):1303-13 [1694723.001]
  • [Cites] Nature. 1990 Aug 2;346(6283):425-34 [1974032.001]
  • [Cites] FASEB J. 1990 Aug;4(11):2868-80 [2199285.001]
  • [Cites] Lab Invest. 1990 Dec;63(6):780-91 [1979361.001]
  • [Cites] Cell. 1991 May 31;65(5):849-57 [1904011.001]
  • [Cites] Cell. 1991 Jul 12;66(1):107-19 [2070412.001]
  • [Cites] Cancer Res. 1994 Dec 1;54(23):6282-7 [7954478.001]
  • [Cites] Gut. 1994 Oct;35(10):1343-7 [7959182.001]
  • [Cites] J Cell Biol. 1994 Dec;127(6 Pt 2):2061-9 [7806582.001]
  • [Cites] Curr Opin Cell Biol. 1994 Oct;6(5):663-73 [7530461.001]
  • [Cites] Cell. 1995 Feb 10;80(3):413-22 [7532110.001]
  • [Cites] Nature. 1995 Mar 23;374(6520):327-37 [7885471.001]
  • [Cites] J Biol Chem. 1995 Mar 10;270(10):5549-55 [7890674.001]
  • [Cites] J Cell Biol. 1995 Jul;130(1):67-77 [7790378.001]
  • [Cites] FASEB J. 1995 Jul;9(10):866-73 [7542213.001]
  • [Cites] J Cell Biol. 1995 Jul;130(2):451-60 [7542249.001]
  • [Cites] Mol Biol Cell. 1995 Apr;6(4):419-31 [7542940.001]
  • [Cites] J Clin Pathol. 1995 Jun;48(6):539-44 [7665697.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Sep 12;92(19):8813-7 [7568023.001]
  • [Cites] J Pathol. 1995 Sep;177(1):11-20 [7472774.001]
  • [Cites] Am J Pathol. 1995 Dec;147(6):1823-39 [7495306.001]
  • [Cites] Curr Opin Cell Biol. 1995 Oct;7(5):634-40 [8573337.001]
  • [Cites] Science. 1996 Apr 5;272(5258):60-6 [8600538.001]
  • [Cites] Cancer Lett. 1996 Apr 19;102(1-2):183-91 [8603368.001]
  • [Cites] Br J Surg. 1996 May;83(5):588-601 [8689199.001]
  • [Cites] Oncology. 1997 Mar-Apr;54(2):158-65 [9075789.001]
  • [Cites] Trends Genet. 1997 Apr;13(4):157-62 [9097727.001]
  • [Cites] Proc Soc Exp Biol Med. 1999 Nov;222(2):124-38 [10564536.001]
  • [Cites] Gut. 2000 Jan;46(1):14-9 [10601048.001]
  • (PMID = 15790695.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Cadherins; 0 / Cell Adhesion Molecules; 0 / Integrins; 0 / Selectins
  • [Number-of-references] 132
  • [Other-IDs] NLM/ PMC1770622
  •  go-up   go-down


99. Kayes OJ, Loddo M, Patel N, Patel P, Minhas S, Ambler G, Freeman A, Wollenschlaeger A, Ralph DJ, Stoeber K, Williams GH: DNA replication licensing factors and aneuploidy are linked to tumor cell cycle state and clinical outcome in penile carcinoma. Clin Cancer Res; 2009 Dec 1;15(23):7335-44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA replication licensing factors and aneuploidy are linked to tumor cell cycle state and clinical outcome in penile carcinoma.
  • We have analyzed replication licensing factors (RLF), together with DNA ploidy status, to investigate their role in progression of penile squamous cell carcinoma and to assess their utility as novel prognostic tools.
  • Accelerated cell cycle progression was linked to increasing tumor size, stage, and depth of invasion.
  • Our results also identify the DNA replication initiation pathway as a potentially attractive therapeutic target in penile squamous cell carcinoma.
  • [MeSH-major] Aneuploidy. Carcinoma / genetics. Carcinoma / therapy. Gene Expression Regulation, Neoplastic. Penile Neoplasms / genetics. Penile Neoplasms / therapy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Sci. 2004 Nov 15;117(Pt 24):5875-86 [15522891.001]
  • [Cites] Clin Cancer Res. 1999 Aug;5(8):2121-32 [10473096.001]
  • [Cites] J Urol. 2005 Mar;173(3):816-9 [15711276.001]
  • [Cites] Clin Cancer Res. 2005 Apr 1;11(7):2510-7 [15814627.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Jun;6(6):476-86 [15928711.001]
  • [Cites] Exp Cell Res. 2005 Sep 10;309(1):56-67 [16005865.001]
  • [Cites] Br J Cancer. 2005 Nov 28;93(11):1295-300 [16278669.001]
  • [Cites] Nat Rev Cancer. 2005 Nov;5(11):845-56 [16239904.001]
  • [Cites] J Urol. 2006 May;175(5):1700-4; discussion 1704-5 [16600735.001]
  • [Cites] J Urol. 2006 Jun;175(6):2103-8; discussion 2108 [16697813.001]
  • [Cites] BJU Int. 2006 Sep;98(3):526-31 [16925747.001]
  • [Cites] Nat Rev Cancer. 2006 Sep;6(9):735-41 [16915294.001]
  • [Cites] Acta Neuropathol. 2007 Feb;113(2):119-27 [17160531.001]
  • [Cites] Br J Cancer. 2007 May 7;96(9):1384-93 [17406359.001]
  • [Cites] Anal Quant Cytol Histol. 2007 Aug;29(4):185-98 [17879626.001]
  • [Cites] Exp Cell Res. 2007 Oct 15;313(17):3789-99 [17689530.001]
  • [Cites] Clin Cancer Res. 2007 Oct 15;13(20):6153-61 [17947481.001]
  • [Cites] Curr Opin Cell Biol. 2007 Dec;19(6):672-9 [18032010.001]
  • [Cites] J Surg Oncol. 2008 May 1;97(6):487-95 [18425779.001]
  • [Cites] Br J Cancer. 2008 May 6;98(9):1548-54 [18414413.001]
  • [Cites] Nat Chem Biol. 2008 Jun;4(6):331-2 [18488006.001]
  • [Cites] Nat Rev Cancer. 2008 Oct;8(10):799-806 [18756287.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2855-64 [18843031.001]
  • [Cites] Br J Cancer. 2009 Mar 24;100(6):959-70 [19240714.001]
  • [Cites] Br J Cancer. 2009 Apr 7;100(7):1128-34 [19293805.001]
  • [Cites] Clin Cancer Res. 2009 Apr 1;15(7):2417-25 [19318489.001]
  • [Cites] Lancet. 1999 Oct 30;354(9189):1524-5 [10551502.001]
  • [Cites] J Cell Sci. 2001 Jun;114(Pt 11):2027-41 [11493639.001]
  • [Cites] Clin Cancer Res. 2001 Sep;7(9):2712-8 [11555583.001]
  • [Cites] Gut. 2002 Mar;50(3):373-7 [11839717.001]
  • [Cites] Trends Cell Biol. 2002 Feb;12(2):72-8 [11849970.001]
  • [Cites] Annu Rev Biochem. 2002;71:333-74 [12045100.001]
  • [Cites] Am J Pathol. 2002 Jul;161(1):267-73 [12107111.001]
  • [Cites] J Natl Cancer Inst. 2002 Jul 17;94(14):1071-9 [12122098.001]
  • [Cites] Nat Rev Cancer. 2003 Mar;3(3):217-26 [12612656.001]
  • [Cites] Br J Cancer. 2003 Sep 15;89(6):1048-54 [12966424.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4306-13 [14645419.001]
  • [Cites] Eur Urol. 2004 Jul;46(1):1-8 [15183542.001]
  • [Cites] Br J Cancer. 2004 Jul 19;91(2):262-9 [15199392.001]
  • [Cites] Br J Cancer. 2004 Aug 16;91(4):714-9 [15266314.001]
  • [Cites] Urol Clin North Am. 1992 May;19(2):247-56 [1574815.001]
  • [Cites] J Urol. 1993 Mar;149(3):492-7 [8437253.001]
  • [Cites] IARC Sci Publ. 1992;(120):45-173 [1284606.001]
  • [Cites] Br J Urol. 1993 Nov;72(5 Pt 2):817-9 [8281416.001]
  • [Cites] Br J Urol. 1993 Dec;72(6):941-5 [8306161.001]
  • [Cites] Am J Surg Pathol. 1998 Jun;22(6):755-61 [9630184.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14932-7 [9843993.001]
  • [Cites] EMBO J. 1998 Dec 15;17(24):7219-29 [9857179.001]
  • [Cites] Anal Cell Pathol. 1998;17(4):189-200 [10391371.001]
  • [Cites] J Pathol. 2005 Feb;205(3):318-28 [15682442.001]
  • (PMID = 19920109.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / A6263
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / GMNN protein, human; 0 / Geminin; 0 / Ki-67 Antigen; 0 / Nuclear Proteins; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2
  • [Other-IDs] NLM/ PMC2788529; NLM/ UKMS27727
  •  go-up   go-down


100. Amano M, Yamaguchi M, Takegawa Y, Yamashita T, Terashima M, Furukawa J, Miura Y, Shinohara Y, Iwasaki N, Minami A, Nishimura S: Threshold in stage-specific embryonic glycotypes uncovered by a full portrait of dynamic N-glycan expression during cell differentiation. Mol Cell Proteomics; 2010 Mar;9(3):523-37

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Threshold in stage-specific embryonic glycotypes uncovered by a full portrait of dynamic N-glycan expression during cell differentiation.
  • We demonstrated that processes of dynamic cellular differentiation of mouse embryonic carcinoma cells, P19CL6 and P19C6, and mouse embryonic stem cells into cardiomyocytes or neural cells can be monitored and characterized quantitatively by profiling entire N-glycan structures of total cell glycoproteins.
  • [MeSH-major] Cell Differentiation. Embryonal Carcinoma Stem Cells / chemistry. Embryonic Stem Cells / chemistry. Glycoproteins / analysis. Myocytes, Cardiac / chemistry. Neurons / chemistry. Polysaccharides / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Biophys Res Commun. 2001 Jun 29;284(5):1098-103 [11414696.001]
  • [Cites] Angew Chem Int Ed Engl. 2008;47(31):5718-38 [18624353.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Apr 26;293(1):167-73 [12054580.001]
  • [Cites] Biochim Biophys Acta. 2002 Dec 19;1573(3):363-8 [12417419.001]
  • [Cites] Annu Rev Biochem. 2004;73:491-537 [15189151.001]
  • [Cites] Curr Biol. 2004 Sep 7;14(17):R691-2 [15341754.001]
  • [Cites] Glycoconj J. 2004;21(1-2):41-5 [15467397.001]
  • [Cites] Proc Natl Acad Sci U S A. 1978 Nov;75(11):5565-9 [281705.001]
  • [Cites] Cell. 1979 Sep;18(1):217-27 [509524.001]
  • [Cites] Nature. 1982 Sep 9;299(5879):165-7 [7110336.001]
  • [Cites] Mol Cell Biol. 1983 Dec;3(12):2280-6 [6656767.001]
  • [Cites] EMBO J. 1983;2(12):2355-61 [6141938.001]
  • [Cites] J Biol Chem. 1989 Jun 5;264(16):9476-84 [2470757.001]
  • [Cites] Glycobiology. 1993 Apr;3(2):97-130 [8490246.001]
  • [Cites] Anal Biochem. 1993 Oct;214(1):70-6 [8250257.001]
  • [Cites] J Biochem. 1993 Sep;114(3):334-8 [8282722.001]
  • [Cites] Cell Struct Funct. 1996 Apr;21(2):101-10 [8790939.001]
  • [Cites] Glycobiology. 1997 Feb;7(1):45-56 [9061364.001]
  • [Cites] Glycobiology. 1999 Aug;9(8):823-31 [10406848.001]
  • [Cites] Angew Chem Int Ed Engl. 2004 Dec 17;44(1):91-6 [15599899.001]
  • [Cites] Nat Med. 2005 Feb;11(2):228-32 [15685172.001]
  • [Cites] Proteomics. 2005 Apr;5(6):1656-68 [15789344.001]
  • [Cites] Stem Cells. 2006 Jan;24(1):145-50 [16253979.001]
  • [Cites] Glycobiology. 2006 Mar;16(3):244-57 [16321922.001]
  • [Cites] Cell. 2006 Sep 8;126(5):855-67 [16959566.001]
  • [Cites] Cell Biol Int. 2006 Oct;30(10):800-7 [16877013.001]
  • [Cites] Proteomics. 2006 Oct;6(20):5650-61 [16972299.001]
  • [Cites] Mol Cell Proteomics. 2006 Nov;5(11):2146-57 [16899540.001]
  • [Cites] Cell. 2007 Apr 6;129(1):123-34 [17418791.001]
  • [Cites] Nature. 2007 Apr 26;446(7139):1023-9 [17460663.001]
  • [Cites] Proteomics. 2007 Mar;7(6):910-20 [17370269.001]
  • [Cites] Curr Opin Chem Biol. 2007 Jun;11(3):300-5 [17500024.001]
  • [Cites] J Cell Biochem. 2007 Sep 1;102(1):149-60 [17520663.001]
  • [Cites] Curr Opin Chem Biol. 2007 Aug;11(4):399-404 [17646122.001]
  • [Cites] Curr Opin Chem Biol. 2007 Aug;11(4):373-80 [17681848.001]
  • [Cites] Cell. 2007 Nov 30;131(5):861-72 [18035408.001]
  • [Cites] J Proteome Res. 2008 Jan;7(1):328-38 [18034457.001]
  • [Cites] Proteomics. 2008 Jan;8(2):264-78 [18203276.001]
  • [Cites] Mol Cell Proteomics. 2008 Feb;7(2):370-7 [17986439.001]
  • [Cites] Anal Chem. 2008 Feb 15;80(4):1094-101 [18205388.001]
  • [Cites] Science. 2002 Jan 4;295(5552):124-7 [11778047.001]
  • (PMID = 20008832.001).
  • [ISSN] 1535-9484
  • [Journal-full-title] Molecular & cellular proteomics : MCP
  • [ISO-abbreviation] Mol. Cell Proteomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glycoproteins; 0 / Polysaccharides
  • [Other-IDs] NLM/ PMC2849713
  •  go-up   go-down






Advertisement